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A B S T R A C T
Background
Schistosoma mansoni is a parasitic infection common in the tropics and sub-tropics. Chronic and advanced disease includes abdominal
pain, diarrhoea, blood in the stool, liver cirrhosis, portal hypertension, and premature death.
Objectives
To evaluate the effects of antischistosomal drugs, used alone or in combination, for treating S. mansoni infection.
Search methods
We searchedMEDLINE, EMBASE and LILACS from inception to October 2012, with no language restrictions. We also searched the
Cochrane Infectious Diseases Group Specialized Register, CENTRAL (The Cochrane Library 2012) and mRCT. The reference lists of
articles were reviewed and experts were contacted for unpublished studies.
Selection criteria
Randomized controlled trials of antischistosomal drugs, used alone or in combination, versus placebo, different antischistosomal drugs,
or different doses of the same antischistosomal drug for treating S. mansoni infection.
Data collection and analysis
One author extracted data and assessed eligibility and risk of bias in the included studies, which were independently checked by a
second author. We combined dichotomous outcomes using risk ratio (RR) and continuous data weighted mean difference (WMD);
we presented both with 95% confidence intervals (CI). We assessed the quality of evidence using the GRADE approach.
Main results
Fifty-two trials enrolling 10,269 participants were included. The evidence was of moderate or low quality due to the trial methods and
small numbers of included participants.
Praziquantel
Compared to placebo, praziquantel 40 mg/kg probably reduces parasitological treatment failure at one month post-treatment (RR
3.13, 95% CI 1.03 to 9.53, two trials, 414 participants, moderate quality evidence). Compared to this standard dose, lower doses may
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be inferior (30 mg/kg: RR 1.52, 95% CI 1.15 to 2.01, three trials, 521 participants, low quality evidence; 20 mg/kg: RR 2.23, 95% CI
1.64 to 3.02, two trials, 341 participants, low quality evidence); and higher doses, up to 60 mg/kg, do not appear to show any advantage
(four trials, 783 participants, moderate quality evidence).
The absolute parasitological cure rate at one month with praziquantel 40 mg/kg varied substantially across studies, ranging from 52%
in Senegal in 1993 to 92% in Brazil in 2006/2007.
Oxamniquine
Compared to placebo, oxamniquine 40 mg/kg probably reduces parasitological treatment failure at three months (RR 8.74, 95% CI
3.74 to 20.43, two trials, 82 participants, moderate quality evidence). Lower doses than 40 mg/kg may be inferior at one month (30
mg/kg: RR 1.78, 95% CI 1.15 to 2.75, four trials, 268 participants, low quality evidence; 20 mg/kg: RR 3.78, 95% CI 2.05 to 6.99,
two trials, 190 participants, low quality evidence), and higher doses, such as 60 mg/kg, do not show a consistent benefit (four trials, 317
participants, low quality evidence).
These trials are now over 20 years old and only limited information was provided on the study designs and methods.
Praziquantel versus oxamniquine
Only one small study directly compared praziquantel 40 mg/kg with oxamniquine 40 mg/kg and we are uncertain which treatment
is more effective in reducing parasitological failure (one trial, 33 participants, very low quality evidence). A further 10 trials compared
oxamniquine at 20, 30 and 60 mg/kg with praziquantel 40 mg/kg and did not show any marked differences in failure rate or percent
egg reduction.
Combination treatments
We are uncertain whether combining praziquantel with artesunate reduces failures compared to praziquantel alone at one month (one
trial, 75 participants, very low quality evidence).
Two trials also compared combinations of praziquantel and oxamniquine in different doses, but did not find statistically significant
differences in failure (two trials, 87 participants).
Other outcomes and analyses
In trials reporting clinical improvement evaluating lower doses (20 mg/kg and 30 mg/kg) against the standard 40 mg/kg for both
praziquantel or oxamniquine, no dose effect was demonstrable in resolving abdominal pain, diarrhoea, blood in stool, hepatomegaly,
and splenomegaly (follow up at one, three, six, 12, and 24 months; three trials, 655 participants).
Adverse events were not well-reported but were mostly described as minor and transient.
In an additional analysis of treatment failure in the treatment arm of individual studies stratified by age, failure rates with 40 mg/kg of
both praziquantel and oxamniquine were higher in children.
Authors’ conclusions
Praziquantel 40 mg/kg as the standard treatment for S. mansoni infection is consistent with the evidence. Oxamniquine, a largely
discarded alternative, also appears effective.
Further research will help find the optimal dosing regimen of both these drugs in children.
Combination therapy, ideally with drugs with unrelated mechanisms of action and targeting the different developmental stages of the
schistosomes in the human host should be pursued as an area for future research.
P L A I N L A N G U A G E S U M M A R Y
Drugs for treating Schistosoma mansoni infection
Schistosoma mansoni is a parasitic worm common in Africa, the Middle East and parts of South America. The worm larvae live in ponds
and lakes contaminated by faeces, and can penetrate a persons’ skin when they swim or bathe. Inside the host, the larvae grow into
adult worms; these produce eggs, which are excreted in the faeces. Eggs rather than worms cause disease. Long-term infection can cause
bloody diarrhoea, abdominal pains, and enlargement of the liver and spleen.
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In this review, researchers in the Cochrane Collaboration evaluated drug treatments for people infected with Schistosoma mansoni. After
searching for all relevant studies, they found 52 trials, including 10,269 people, conducted in Africa, Brazil and the Middle East. Most
trials report on whether or not the treatment stops eggs excretion; three reported the persons recovery from symptoms.
The results show that a single dose of praziquantel (40 mg/kg), as recommended by the World Health Organization, is an effective
treatment for Schistosoma mansoni infection. Lower doses may be less effective, and higher doses probably have no additional benefit.
Oxamniquine (40 mg/kg), though now rarely used, is also effective. Again, lower doses may be less effective and no advantage has been
demonstrated with higher doses.
Only one study directly compared praziquantel 40 mg/kg with oxamniquine 40 mg/kg, and based on this limited evidence, we are
uncertain which intervention is more effective. Adverse events were not well reported for either drug, but were mostly described as
minor and transient.
In children aged less than 5 years, there is limited evidence that these doses may be less effective, and further research will help optimise
the dose for this age-group.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Praziquantel 40 mg/kg for treating S. mansoni infection
Patient or population: People with S. mansoni infection
Settings: Endemic settings
Intervention: Praziquantel 40 mg/kg
Outcomes Comparison Illustrative comparative risks1 (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Praziquantel 40 mg/kg Comparator
Parasitological failure
at 1 month
versus placebo 22 per 100 69 per 100
(23 to 100)
RR 3.13
(1.03 to 9.53)
414
(2 trials)
⊕⊕⊕©
moderate2,3,4
versus 20 mg/kg 22 per 100 50 per 100
(34 to 72)
RR 2.23
(1.64 to 3.02)
341
(2 trials)
⊕⊕©©
low4,5
versus 30 mg/kg 22 per 100 33 per 100
(25 to 44)
RR 1.52
(1.15 to 2.01)
521
(3 trials)
⊕⊕©©
low4,5
versus 60 mg/kg 22 per 100 21 per 100
(16 to 28)
RR 0.97
(0.73 to 1.29)
783
(4 trials)
⊕⊕⊕©
moderate6,7
versus split dose 22 per 100 10 per 100
(3 to 37)
RR 0.47
(0.13 to 1.69)
525
(2 trials)
⊕⊕©©
low4,8
*The basis for the assumed risk is given in the footnotes.
The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
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GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Treatment failure with praziquantel 40 mg/kg ranged from 5% to 48% in the included studies. The risk given here is the median risk in
these studies and is given for illustrative purposes.
2 No serious risk of bias. Both studies adequately concealed allocation and blinded participants and investigators. Loss to follow-up was
high in one study.
3 No serious inconsistency: Both trials showed statistically significant benefits with praziquantel but the size of the effect varied. In Kenya
in 1999 failure with praziquantel was 43% at one month and in Uganda in 2009 it was 18%.
4 Downgraded by 1 for indirectness: Only two trials from limited settings have evaluated this comparison.
5 Downgraded by 1 for risk of bias: These trials are more than twenty years old and do not provide an adequate description of methods
to reduce the risk of bias.
6 No serious risk of bias: The three trials by Olliaro in 2010 adequately concealed allocation and blinded participants and investigators to
be considered at low risk of bias.
7 Downgraded by 1 for indirectness: The trials so far do not indicate a benefit with higher doses than 40 mg/kg. However, we cannot be
certain that there might not be some benefit in specific settings.
8 Downgraded by 1 for inconsistency: One trial found a significant benefit with splitting the dose and one did not. The trials were of
similar size and power.
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B A C K G R O U N D
Description of the condition
Schistosomiasis is a parasitic blood fluke infection, of which three
species commonly infect humans; Schistosoma mansoni (common
in the tropics and sub-tropics), S. haematobium (mostly endemic
in Africa and the Middle East) and S. japonicum (endemic in the
People’s Republic of China and the Philippines) (Engels 2002;
WHO 2002; Gryseels 2006; Steinmann 2006; Utzinger 2009).
It has been estimated that 779 million people are at risk of schis-
tosomiasis worldwide and 207 million people may be infected
(Steinmann 2006). Of these, 120 million people are estimated to
be symptomatic and 20 million suffer from long-term complica-
tions (Chitsulo 2000; WHO 2002; van der Werf 2003). In global
burden of disease estimates, schistosomiasis causes 1.7 to 4.5 mil-
lion disability-adjusted life years (DALYs) (WHO 2002; WHO
2004; Hotez 2006; Steinmann 2006; Utzinger 2009). Some sug-
gest that this value may underestimate the true burden of schis-
tosomiasis (WHO 2002; van der Werf 2003; King 2005; King
2007; King 2008a; King 2010).
People infected with S. mansoni excrete the fluke eggs in their fae-
ces, and faecal contamination of freshwater allows these eggs to
hatch into larvae (miracidia) which penetrate a specific freshwa-
ter snail (the intermediate host). Within the snail, the miracidia
develop into cercariae (the infective larvae), which can penetrate
a person’s skin upon contact with contaminated water bodies.
Following infection, the worms migrate through the human ve-
nous system, via the right chamber of the heart and the lungs,
and through the mesenteric arteries and the liver via the portal
vein, before finally settling in the superior mesenteric veins which
drain the large intestine. Here, male and female worms mature,
pair up and the female worms start to produce eggs ( 300 per
day) (Davis 2009). An adult worm usually lives for three to five
years, but some can live up to 30 years (Gryseels 2006). The eggs
produced by the worms traverse the intestinal wall to be excreted
in the faeces, and in the process some become trapped and ini-
tiate inflammatory reactions, which cause the underlying pathol-
ogy and symptomatic illness (Richter 2003a; King 2008b). Early
symptoms depend on the severity of infection (Gryseels 1987),
and if treatment is not provided early, chronic illness and long-
term serious disease can follow.
Symptoms and effects
Schistosomiasis mansoni can present as an acute or chronic illness.
The acute illness, or Katayama syndrome, is caused by migrating
and maturing schistosomula that may result in a systemic hyper-
sensitivity reaction characterized by fever, feeling of general dis-
comfort (malaise), muscle pain (myalgia), fatigue, non-productive
cough, diarrhoea (with or without blood), and pain in the upper
right part of the abdomen just below the rib cage. Chronic and
advanced disease results from the host’s immune response to schis-
tosome eggs deposited in tissues and the granulomatous reaction
evoked by the antigens they secrete and is characterized by non-
specific intestinal symptoms, such as abdominal pain, diarrhoea
and blood in the stool (Gryseels 1992; Gray 2011; Gryseels 2012).
Inflammatory reactions in the liver lead to hepatosplenic schisto-
somiasis, a key feature of chronic infection, which can manifest
within a couple of months for heavy infections or many years af-
ter light infections. The chronic inflammation produces fibrotic
lesions, which in turn lead to liver cirrhosis that progressively oc-
cludes the portal system giving rise to portal hypertension. The
portal hypertension eventually leads to enlargement of hepatic ar-
teries, and the associated oesophageal varices may rupture with
heavy blood loss, haemorrhagic shock and death. The patient may
also suffer repeated episodes of variceal bleeding - the primary
cause of death in hepatic schistosomiasis (Andersson 2007). Sever-
ity of disease depends upon the intensity and duration of infec-
tion (Naus 2003), but recent evidence suggests the presence of the
infection alone determines morbidity (King 2008a).
S. mansoni infection overlaps in distribution with S. haematobium
in some areas of sub-Saharan Africa resulting in mixed infections
(WHO 2002). Unlike S. mansoni, the main early symptoms of S.
haematobium infection are blood inurine (haematuria) andpainful
urination (dysuria). Chronic and advanced disease is insidious and
may result in structural damage to the bladder wall which may
eventually lead to kidney failure.
Diagnosis
Definitive diagnosis of S. mansoni infection is by microscopy for
parasite eggs in the stool. Quantitative methods are recommended
for epidemiological purposes because they allow estimation of in-
tensity and evaluation of the impact of control programmes not
only in terms of cure rate but also egg reduction rate (WHO1985;
Doenhoff 2004; Bergquist 2009). The Kato-Katz technique (Katz
1972) is the most common quantitative technique (Booth 2003).
Recently, the FLOTAC technique has been applied for the detec-
tion and quantification of S. mansoni eggs in stools with promising
results and hence warranting further investigation (Glinz 2010).
Egg output can be influenced by several factors, such as day-to-
day, intra-stool, and seasonal variations as well as environmental
conditions (Braun-Munzinger 1992; Engels 1996; Engels 1997;
Enk 2008). Therefore negative results following microscopic ex-
amination of a single stool are unreliable (de Vlas 1992; Kongs
2001; Booth 2003; Enk 2008), and measurement of prevalence
and intensity of infection by egg count has shortcomings (Gryseels
1996; de Vlas 1997; Utzinger 2001a). Rectal biopsy is more sensi-
tive than microscopy and is occasionally done when repeated stool
examinations are negative for eggs. However, this method is un-
suitable for use in population-based control programmes (Allan
2001).
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A monoclonal antibody-based dipstick is increasingly being used
for the diagnosis of the infection with promising results (Polman
2001; Legesse 2007; Legesse 2008; Caulibaly 2011). A more spe-
cific and sensitive diagnostic technique based on polymerase chain
reaction (PCR) is increasingly being used in some reference labora-
tories in Europe (Sandoval 2006; Cnops 2012; Enk 2012). Ultra-
sound is used for diagnosing and assessing infection-related pathol-
ogy (Hatz 1990; Mohamed-Ali 1991; Doehring-Schwerdtfeger
1992; Hatz 2001; Richter 2003b).
Clinically, intestinal schistosomiasis is diagnosed on the basis of
presence of blood in stool, (bloody) diarrhoea, and abdominal
pain, but these are non-sensitive and non-specific (Gryseels 1992;
Utzinger 2000c; Danso-Appiah 2004) as diarrhoea or blood in
stool can be due to other causes such as hookworm infection,
dysentery and typhoid fever.
Description of the intervention
Schistosomiasis control measures implemented before the 1970s
- when efficacious antischistosomal drugs were not available - fo-
cused mainly on interrupting transmission with molluscicides to
kill the intermediate host snails (WHO 1985; Sturrock 2001).
The 1970s marked the turning point in schistosomiasis control
when efficacious drugs that can be applied in a single oral dose
were discovered, shifting the control emphasis from transmis-
sion control to chemotherapy-based morbidity control (WHO
1985; Cioli 1995). A body of evidence suggests that morbid-
ity due to schistosomiasis can be prevented and pathology re-
versed with available antischistosomal treatments (Mohamed-Ali
1991; Doehring-Schwerdtfeger 1992; Savioli 2004; Zhang 2007;
Webster 2009; Koukounari 2010).
Mass drug administration, or treatment of infected individuals or
entire ’at-risk’ populations (eg school-aged children), usually with-
out prior diagnosis - an approach termed ’preventive chemother-
apy’, is the control strategy currently pursued by theWorldHealth
Organization (WHO) and applied in many endemic countries
(WHO2006). Usually, praziquantel at a single 40mg/kg oral dose
is used (Fenwick 2009), but still there are uncertainties regarding
this dose. An exception is Brazil where the national policy adopted
since 1995 recommends a single oral dose of 60 mg/kg for chil-
dren aged between two and 15 years, and 50mg/kg for adolescents
and adults (Favre 2009). The recently adopted policy for schisto-
somiasis control in Brazil disapproves of treatment without prior
diagnosis, and therefore the preventive chemotherapy strategy is
no longer applied in Brazil (Favre 2009).
Oxamniquine has also been used extensively for the control of
schistosomiasis mansoni in different endemic countries, most no-
tably Brazil, where more than 12 million doses of oxamniquine
have been administered by the national schistosomiasis control
programme (Katz 2008). There are uncertainties around the stan-
dard dose of oxamniquine (Foster 1987; Cioli 1995). Therefore,
the WHO recommends total doses of 20 to 60 mg/kg (in divided
doses of up to 20 mg/kg) (WHO 2001).
More recently, the artemisinin derivatives used in the treatment
of malaria have been shown to have antischistosomal properties,
particularly against the immature developing stages of the schisto-
some parasites (Borrmann 2001; Utzinger 2007). Praziquantel, in
contrast, acts against the adult worms and the very young schisto-
somula just after skin penetration (Sabah 1986; Utzinger 2007).
The current emphasis of schistosomiasis control is to reduce the
burden of disease in high endemicity areas and to interrupt trans-
mission in low endemicity areas (WHO 2002). Intensity of in-
fection is highest in school-aged children and adolescents, there-
fore preventive chemotherapy is targeted especially to these at-
risk groups (Magnussen 2001; WHO 2002; Savioli 2004; Savioli
2009).
The efficacy of myrrh (Mirazid) in the treatment of intestinal
schistosomiasis has been evaluated in Egypt (Barakat 2005 EGY;
Botros 2005 EGY).
Why it is important to do this review
Currently, entire control and treatment programmes are based
on praziquantel and there is risk of drug resistance and perhaps
shortages of praziquantel. There is a need to assess alternative drugs
or combinations. Still there are uncertainties around effective and
safe dosage of praziquantel and standard doses of oxamniquine.
There are also uncertainties about adequacy of current adult doses
used in children.
O B J E C T I V E S
To evaluate the effects of antischistosomal drugs, used alone or in
combination, for treating S. mansoni infection.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials.
Types of participants
Individuals infectedwith S. mansoni diagnosedmicroscopically for
the presence of S. mansoni eggs in stool using the Kato-Katz tech-
nique (Katz 1972), or any other quantitative diagnostic method,
such as the quantitative oogram and FLOTAC techniques.
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Types of interventions
The following comparisons are evaluated in this review:
1. Antischistosomal drugs alone or in combination versus
placebo;
2. Antischistosomal drugs alone or in combination versus a
different dose of the same antischistosomal drug; and
3. Antischistosomal drugs alone or in combination versus
different antischistosomal drugs alone or in combination.
Trials that allocated non-schistosomal drug or interventions in ad-
dition to the treatment and control of interest were eligible pro-
vided the same drug was allocated to both treatment and control
groups.
Types of outcome measures
Primary outcomes
• Parasitological failure, defined as treated individuals who
remained positive for S. mansoni eggs in stool using the standard
Kato-Katz or other quantitative techniques (follow-up: up to one
month).
• Egg reduction rate, defined as percent reduction in S.
mansoni egg count after treatment (follow-up: up to 12 months).
Secondary outcomes
• Parasitological failure (follow-up: greater than one month).
• Resolution of symptoms (eg abdominal pain, diarrhoea and
bloody diarrhoea).
• Resolution of pathology (eg hepatomegaly, splenomegaly,
portal fibrosis, cirrhosis of the liver or colonic polyps) measured
by ultrasound, by standard international classification or other
standardized methods (CWG 1992).
Adverse events
• Non-serious adverse events.
• Serious adverse events (ie any untoward medical occurrence
or effect that at any dose: results in death; is life-threatening;
requires hospitalisation or prolongation of existing inpatients’
hospitalisation; results in persistent or significant disability or
incapacity; is a congenital anomaly or birth defect).
Search methods for identification of studies
We attempted to identify all relevant trials regardless of language or
publication status (published, unpublished, in press, under review
and in progress).
Electronic searches
Databases
We searched the following databases using the search terms and
strategy described in Table 1: Cochrane Infectious Diseases Group
Specialized Register (October 2012); Cochrane Central Register
of Controlled Trials (CENTRAL), published in the Cochrane Li-
brary; MEDLINE (1966 to October 2012); EMBASE (1974 to
October 2012); and LILACS (1982 to October 2012). We also
searched the metaRegister of Controlled Trials (mRCT) in Octo-
ber 2012 using ’Schisto * mansoni’ as the search term.
Searching other resources
Researchers and organizations
We contacted individual researchers working on antischistosomal
drugs, pharmaceutical industries and experts from the UNICEF/
UNDP/World Bank/WHO Special Programme for Research and
Training in Tropical Diseases (TDR) for unpublished data and
ongoing trials.
Reference lists
We checked the reference lists of all studies identified by the afore-
mentioned methods for additional relevant studies.
Data collection and analysis
Selection of studies
Vittoria Lutje, the Cochrane Infectious Diseases Group (CIDG)
Information Retrieval Specialist, searched the literature and re-
trieved studies using the search strategy outlined in Table 1. An-
thony Danso-Appiah (ADA) screened the results to identify po-
tentially relevant trials, obtained the full trial reports and assessed
the eligibility of trials for inclusion in the review using an eligibil-
ity form based on the inclusion criteria. Jürg Utzinger (JU) inde-
pendently verified the eligibility assessment results.
ADA contacted the authors of potentially relevant trials for clari-
fication if eligibility was unclear. We excluded studies that did not
meet our inclusion criteria and we have detailed the reasons for
exclusion in the Characteristics of excluded studies. This was veri-
fied independently by JU and Piero L. Olliaro (PLO).We resolved
any discrepancies through discussion between the authors.
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Data extraction and management
ADA extracted trial characteristics such as methods, participants,
interventions and outcomes, and recorded on standard forms,
which were independently verified by JU. ADA and JU resolved
discrepancies through discussion, and where necessary contacted a
third author (PLO). ADA contacted trial authors for clarification,
or insufficient or missing data when necessary.
We extracted the number of participants randomized and the num-
ber of patients followed-up in each treatment arm. For dichoto-
mous outcomes, we recorded the number of participants experi-
encing the event in each treatment group of the trial. For con-
tinuous outcomes summarized as geometric means, we extracted
means and their standard deviations (SD) on the log scale. If the
data were summarized as arithmetic mean, we extracted themeans
and their SDs. We extracted medians or ranges when they were
reported to summarize the data.
For each outcome, we extracted data for each follow-up time re-
ported in the trial report.
Assessment of risk of bias in included studies
ADA assessed the risk of bias of each trial using The Cochrane
Collaboration’s risk of bias tool (Higgins 2011) and the assess-
ment results were verified independently by Dave Sinclair (DS).
Where information in the trial report was unclear, we attempted
to contact the trial authors for clarification. We assessed the risk
of bias for six domains: sequence generation, allocation conceal-
ment, blinding (investigators, outcome assessors and participants),
incomplete outcome data, selective outcome reporting and other
sources of bias. For each domain, wemade a judgment of ’low risk’
of bias, ’high risk’ of bias or ’unclear’. We resolved any discrepan-
cies by discussion between the authors.
Measures of treatment effect
Wepresented dichotomous outcomes using risk ratios (RR).Mean
differences (MD) were used as the measure of effect for continu-
ous outcomes that were summarized as arithmetic means.We used
geometric mean ratios for continuous outcomes that were sum-
marized as geometric means. We presented all results with 95%
confidence intervals (CI).
Dealing with missing data
We analysed data based on the number of patients for whom an
outcome was recorded (complete case analysis).
Assessment of heterogeneity
We assessed heterogeneity by inspecting the forest plots for over-
lapping CIs and outlying data; using the Chi2 test with a P value
< 0.1 to indicate statistically significant heterogeneity; and using
the I2 statistic.
Assessment of reporting biases
Wewould have attempted to explore publication bias using funnel
plots if there were sufficient number of trials in the comparisons.
Data synthesis
We used Review Manager (RevMan) to perform the statistical
analyses. We stratified the analyses by: comparison; the dose of
the drug; and the length of follow-up time. We used meta-anal-
ysis to combine the results across trials. When heterogeneity was
detected, we used a random-effects meta-analysis approach; oth-
erwise a fixed-effect approach was adopted. We tabulated adverse
events and also data that could not be meta-analysed.
Subgroup analysis and investigation of heterogeneity
When heterogeneity was detected, we planned to carry out sub-
group analyses to explore potential causes. Subgroupings would
be as follows: patient age (children versus adults); and intensity of
infection (< 500 eggs per gram of stool versus > 500 eggs per gram
of stool).
We conducted a subsidiary, non-randomized comparison of failure
rates in children with failure rates in adults for the same drug and
same dose (mg/kg) to explore issues around dose applicability in
children.
Sensitivity analysis
Where data were sufficient we planned to conduct sensitivity anal-
yses to assess the robustness of the results to the risk of bias com-
ponents.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
We identified 52 trials (10,269 participants) which met the inclu-
sion criteria (see Characteristics of included studies). We managed
one multicentre trial carried out in Brazil, Mauritania and Tan-
zania as three separate trials in the analysis (Olliaro 2011 BRA;
Olliaro 2011 MRT; Olliaro 2011 TZA), and three papers con-
tained multiple individual studies which we again managed sepa-
rately (de Clarke 1976a ZWE; de Clarke 1976b ZWE; de Clarke
1976c ZWE; de Clarke 1976d ZWE; Katz 1979a BRA; Katz
1979b BRA; Gryseels 1989a BDI; Gryseels 1989b BDI; Gryseels
1989c BDI).
Of the 52 trials we identified, 19 evaluated praziquantel, 17 eval-
uated oxamniquine and 12 directly compared praziquantel with
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oxamniquine. In addition, two compared myrrh (mirazid) with
praziquantel, and two compared different brands of praziquantel.
Three trials assessed combination therapies: including praziquan-
tel plus oxamniquine (Creasey 1986 ZWE; Zwingenberger 1987
BRA) and praziquantel plus artesunate (De Clercq 2000 SEN).
For the two primary outcomes, 47 trials reported cure rate or fail-
ure rate, 34 trials reported egg reduction rate and 33 trials reported
both outcomes. Only Sukwa 1993 ZMB reported reinfection rate.
For secondary outcomes, five trials (Rugemalila 1984 TZA;
Gryseels 1989a BDI; Gryseels 1989b BDI; Gryseels 1989c BDI;
Sukwa 1993 ZMB) reported clinical improvement or functional
indices, but we could not include Rugemalila 1984 TZA and
Sukwa 1993 ZMB in the meta-analysis because of insufficient in-
formation. Thirty-three trials reported adverse events.
In the study by de Jonge 1990 SDN,we excluded the two arms that
received metrifonate and placebo respectively from the analysis.
Also, we excluded one arm of the study by Ibrahim 1980 SDN
involving participants who did not have S. mansoni infection and
also one arm each of the trials by Rugemalila 1984 TZA andTaylor
1988 ZWE that did not receive treatment from the analysis.
The trial by Tweyongyere 2009 UGA assessing the effects of prazi-
quantel was a nested cohort study within a larger mother and baby
cohort study in which pregnant women found to be infected with
S. mansoniwere randomized to receive praziquantel or placebo.We
obtained data on parasitological failure rate and clinical improve-
ment from figures (Gryseels 1989a BDI; Gryseels 1989b BDI;
Gryseels 1989c BDI), but it was not possible to extract egg count
data.
Trial setting and participants
The trials were conducted in Africa (n = 36), South America (n
= 15; all in Brazil) and the Middle East (n = 1). Eight trials were
conducted in the late 1970s, 28 in the 1980s, seven in the 1990s
and only nine since the year 2000.
Eighteen trials involved children, 12 trials recruited adults, and
22 recruited whole populations comprising children, adolescents
and adults.
Seventeen trials recruited participants from the outpatient clinics,
six did not specify the setting whilst one trial (Omer 1981 SDN)
consisted of both participants identified in a field survey and those
attending the hospital; two trials (Katz 1979a BRA; Katz 1979b
BRA) involvedmilitary officers in a Barracks who became exposed
to the infection during training and another trial (Ibrahim 1980
SDN) recruited university students on campus. The remaining 25
trials recruited participants through community surveys.
Risk of bias in included studies
For risk of bias of included studies see the Characteristics of
included studies and summary of the risk of bias graph (Figure 1)
and risk of bias summary (Figure 2).
Figure 1. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
We considered 16 trials as low risk of bias with regard to the gener-
ation of the randomization sequence (Figure 2). In the remaining
36 trials, the methods used to generate the sequence of allocation
were not described and therefore the risk of bias is unclear.
Fourteen trials adequately described allocation concealment and
had a low risk of bias. One trial did not conceal allocation
(Fernandes 1986 BRA); and the methods were unclear in the re-
maining 37 trials (Figure 2).
Blinding
Twenty-seven trials employed blinding and stated who was
blinded. However, none described the methods of blinding. Nev-
ertheless, the studies were considered to be at low risk of bias.
One trial did not employ blinding (Fernandes 1986 BRA) and we
therefore classed it at high risk of bias; whereas in 25 trials blinding
was unclear (Figure 2).
Incomplete outcome data
We considered the risk of bias for incomplete outcome data to be
low in 17 trials (Figure 2). We deemed the risk of bias to be high
in 19 trials, and in the remaining 16 trials as unclear.
Selective reporting
All 52 trials had low risk of selective outcome reporting (Figure
2).
Other potential sources of bias
Overall, 42 trials were considered to be free from other biases and
the level of bias was unclear in the remaining 10 trials (Figure 2).
Effects of interventions
See:Summary offindings for themain comparisonPraziquantel
40 mg/kg for treating S. mansoni infection; Summary of
findings 2 Oxamniquine 40 mg/kg for treating S. mansoni
infection; Summary of findings 3Oxamniquine 40 mg/kg versus
praziquantel 40 mg/kg; Summary of findings 4 Artesunate (12
mg/kg) plus praziquantel (40 mg/kg) versus praziquantel (40
mg/kg) alone
Section 1. Monotherapies
Praziquantel
Nineteen trials, conducted in Africa, Brazil and the Arabian Pe-
nunsula, evaluated praziquantel. Four studies compared prazi-
quantel with placebo, and 17 trials directly compared different
dosing schedules of praziquantel with the standard dose of 40 mg/
kg.
Analysis 1: Praziquantel versus placebo
Parasitological failure
Two trials fromKenya andUganda used theWHO recommended
dose of 40 mg/kg. Praziquantel 40 mg/kg achieved parasitological
cure in 57% and 82% of the patients respectively, compared to
placebo where almost all continued to excrete eggs at one to two
months (RR 3.13, 95% CI 1.03 to 9.53, two trials, 414 partici-
pants, Analysis 1.1).
In addition, one small trial from Brazil compared three different
doses of praziquantel with placebo and presented outcomes at six
and 12 months. All patients given 40 mg/kg and 60 mg/kg prazi-
quantel achieved parasitological cure at six months, while two out
of five patients given 20 mg/kg and almost all those given placebo
continued to excrete eggs (one trial, 40 participants, Analysis 1.2).
At 12months, reinfectionwas demonstrable in some of those given
praziquantel (Analysis 1.3). One further trial from Brazil gave 60
mg/kg praziquantel each day for three days and achieved 100%
parasitological cure at six months compared to almost complete
failure with placebo (one trial, 55 participants, Analysis 1.2).
Egg reduction
None of these trials reported on percentage egg reduction.
Adverse events
No serious adverse events were recorded in these trials but transient
dizziness and abdominal pain appeared to be more commonly re-
ported with praziquantel than placebo (seven trials, 1255 partici-
pants, Table 2).
Analyses 2 and 3: Lower doses praziquantel versus 40 mg/kg
Parasitological failure
Lower doses (20 mg/kg to 30 mg/kg) have been evaluated in Zim-
babwe, Burundi, Sudan and Brazil. Compared to 40 mg/kg, par-
asitological failure at one month was more than double with the
20 mg/kg dose, and 50% higher with the 30 mg/kg dose (20 mg/
kg: RR 2.23, 95% CI 1.64 to 3.02, two trials, 341 participants;
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30 mg/kg: RR 1.52, 95% CI 1.15 to 2.01, three trials, 521 par-
ticipants; Analysis 2.1). Follow-up at three months (Analysis 2.2)
and at six to 12 months showed a similar pattern (Analysis 2.3).
Egg reduction
In one trial from Brazil evaluating 30 mg/kg versus 40 mg/kg,
geometric mean egg reductions were high in both groups, at six
months (92.5% versus 97.7%, statistical significance not reported
(one trial, 138 participants, Analysis 2.4)).
Symptom resolution
One trial compared a lower dose of praziquantel at 20 mg/kg with
40 mg/kg and showed no difference in resolving symptoms at
three, six, 12 and 24 months of follow-up: diarrhoea (one trial,
44 participants, Analysis 3.3), blood in stool (one trial, 37 par-
ticipants, Analysis 3.5), hepatomegaly (one trial, 55 participants,
Analysis 3.7) and splenomegaly (one trial, 73 participants, Analy-
sis 3.9), except one study that showed that 40 mg/kg significantly
improved abdominal pain at one month (RR 0.59, 95% CI 0.36
to 0.98, one trial, 169 participants, Analysis 3.1).
Two trials compared 30 mg/kg with 40 mg/kg and did not show
any difference in resolving symptoms at one, three, six, 12 and
24 months of follow-up: abdominal pain (two trials, 318 par-
ticipants, Analysis 3.2), diarrhoea (two trials, 48 participants,
Analysis 3.4), blood in stool (two trials, 82 participants, Analysis
3.6), hepatomegaly (two trials, 109 participants, Analysis 3.8) and
splenomegaly (two trials, 122 participants, Analysis 3.10).
Adverse events
In the three trials reporting adverse events, consistent differences
in frequency or severity between 20, 30 and 40 mg/kg doses have
not been shown (three trials, 319 participants, Table 3).
Analysis 4: Higher doses praziquantel versus 40 mg/kg
Parasitological failure
Higher doses (50mg/kg to 60mg/kg) have been evaluated inBrazil
(three trials), Mauritania, Senegal and Tanzania. Compared to 40
mg/kg, parasitological failure has not been shown to be improved
with higher doses at one month (five trials, 783 participants, Anal-
ysis 4.1).
Egg reduction
Among participants still excreting eggs, percentage egg reductions
were similar in both groups at one month (four trials, 786 partic-
ipants, Analysis 4.4).
Adverse events
One multi-country trial reported adverse events and recorded one
serious event (a seizure) with the higher dose. At the trial site in
Brazil, non-severe adverse events appeared to be more common
with the higher dose but this was not seen consistently at the trial
sites in Mauritania or Tanzania (one trial, 653 participants, see
Table 4).
Analysis 5: Split dose praziquantel versus 40 mg/kg in a
single dose
Splitting 40 mg/kg into divided doses given on the same day was
evaluated in the 1980s in three trials in Sudan.
Parasitological failure
At one month, two trials did not demonstrate a statistically sig-
nificant benefit with the split dose regimen compared to a single
40 mg/kg dose (two trials, 525 participants, Analysis 5.1), but
showed benefit at three months (RR 0.31, 95% CI 0.18 to 0.53,
two trials, 516 participants, Analysis 5.2).
One further small trial, only reported the outcome at six months
and found no difference (one trial, 64 participants, Analysis 5.3).
Egg reduction
In the only trial reporting egg count, the mean percent reduction
at one month was higher with the divided dose but statistical
significance was not reported (divided dose 93.2% versus single
dose 86.5%, one trial, 350 participants, Analysis 5.4).
Adverse events
No serious adverse events were reported in these trials. Only one
trial reported the frequency of adverse events in each treatment
group (Kardaman 1983 SDN). Mild abdominal pain and diar-
rhoea were less common when the dose was given in divided doses
but vomitingwasmore common (one trial, 350 participants, Table
5).
Analysis 6: Other praziquantel dosing regimens
Several trials fromBrazil have evaluated higher praziquantel dosing
regimens with 30 mg/kg to 60 mg/kg given for up to six days
(see Analysis 6.1). It is difficult to draw conclusions from these
studies as the comparator dose is also a non-standard regimen, but
one trial did demonstrate improved parasitological cure rates with
prolonged courses given over three to six days compared to courses
lasting one day.
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Adverse events
No serious adverse events were reported in these trials, events were
mainly transient dizziness and nausea (one trial, 79 participants,
Table 6).
Oxamniquine
Seventeen trials evaluated oxamniquine, with themost recent con-
ducted in the 1980s. Oxamniquine has since fallen out of use in
favour of praziquantel. Four trials compared oxamniquine with
placebo and 12 trials directly compared different dosing schedules
of oxamniquine in different geographical locations in Africa and
Brazil. The most common comparator dose was 40 mg/kg.
Analysis 7: Oxamniquine versus placebo
Parasitological failure
In two trials in Brazil, 20 mg/kg was significantly superior to
placebo at longer timepoints (RR 3.68, 95% CI 2.53 to 5.36, two
trials, 146 participants, Analysis 7.2). In two trials from Ethiopia,
oxamniquine achieved parasitological cure rates of > 75%with 30,
40, and 60 mg/kg at three to four months, compared to placebo
where almost all participants continued to excrete eggs (30 mg/
kg: RR 4.34, 95% CI 2.47 to 7.65, two trials, 82 participants; 40
mg/kg: RR 8.74, 95% CI 3.74 to 20.43, two trials, 82 partici-
pants; 60 mg/kg: RR 19.38, 95% CI 5.79 to 64.79, two trials, 89
participants; Analysis 7.1).
Egg reduction
Among those still excreting eggs at three to four months, two trials
from Ethiopia reported significant reductions in egg numbers in
those given oxamniquine (68.1% to 100%), compared to increases
of 59 to 80.6% in the placebo groups (two trials, 227 participants,
Analysis 7.3).
Adverse events
No serious adverse events were reported in these trials. Dizziness
was more commonly reported with oxamniquine than placebo but
is described as transient, with most resolving within 24 hours (five
trials, 425 participants, Table 7).
Analyses 8 and 9: Lower doses oxamniquine versus 40 mg/kg
Lower doses of oxamniquine (20 to 30mg/kg) have been compared
to 40mg/kg in Ethiopia (two trials), Sudan (two trials), Zimbabwe
(two trials), Burundi and Malawi.
Parasitological failure
Compared to 40 mg/kg, both 20 mg/kg and 30 mg/kg of oxam-
niquine resulted in significantly more parasitological failures at
one month (20 mg/kg: RR 3.78, 95% CI 2.05 to 6.99, two trials,
190 participants; 30 mg/kg: RR 1.78, 95% CI 1.15 to 2.75, four
trials, 268 participants, Analysis 8.1), and at three to four months
(20 mg/kg: RR 2.28, 95% CI 1.40 to 3.71, three trials, 209 par-
ticipants; 30 mg/kg: RR 1.64, 95% CI 1.10 to 2.43, seven trials,
373 participants, Analysis 8.2).
At later time points, no statistically significant differences were
shown: six months (20 mg/kg: two trials, 163 participants; 30
mg/kg: three trials, 214 participants, Analysis 8.3) and 12 months
(20 mg/kg: two trials, 144 participants; 30 mg/kg: one trial, 77
participants, Analysis 8.4).
Egg reduction
Percent egg reduction was evaluated in six of these trials and both
lower dose and 40 mg/kg showed a wide range of benefit at one,
three and six months: lower dose (57.1% to 99%) and 40 mg/kg
(42.7 to 100%) (six trials, 878 participants, Analysis 8.5).
Symptom resolution
One trial compared a lower dose of 20 mg/kg oxamniquine with
40 mg/kg and did not find any difference between the two doses
in resolving symptoms at one, three, six, 12 and 24 months of
follow-up: abdominal pain (one trial, 95 participants, Analysis
9.1), diarrhoea (one trial, 16 participants, Analysis 9.3), blood in
stool (one trial, 85 participants, Analysis 9.5), hepatomegaly (one
trial, 64 participants, Analysis 9.7) and splenomegaly (one trial,
69 participants, Analysis 9.9).
Also, 30 mg/kg did not show any difference statistically com-
pared with 40 mg/kg in resolving symptoms at one, three, six,
12 and 24 months of follow-up: abdominal pain (one trial, 95
participants, Analysis 9.2), diarrhoea (one trial, 15 participants,
Analysis 9.4), blood in stool (one trial, 41 participants, Analysis
9.6), hepatomegaly (one trial, 51 participants, Analysis 9.8) and
splenomegaly (one trial, 54 participants, Analysis 9.10).
Adverse events
Six trials from Ethiopia (two trials), and one trial each from
Malawi, Sudan, Zambia and Zimbabwe assessed adverse events
and reported no serious events. Dizziness was most commonly
reported, but the event rate and severity did not differ between
doses (six trials, 508 participants, Table 8).
Analysis 10: Higher doses oxamniquine versus 40 mg/kg
Higher doses of oxamniquine (50 mg/kg to 60 mg/kg) have been
compared to 40 mg/kg in six trials from three countries; Sudan
(three trials), Ethiopia (two trials) and Zambia (one trial).
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Parasitological failure
Higher doses of oxamniquine have not shown consistent statisti-
cally significant benefits over 40 mg/kg at one month (five trials,
349 participants, Analysis 10.1), at three to four months (six trials,
397 participants, Analysis 10.2), or six months (two trials, 177
participants, Analysis 10.3).
Losses to follow-up were high in the trial investigating 50 mg/kg,
reaching 76.9% at three months, and heterogeneity between the
trials was significant (I2= 64% to 82%).
Egg reduction
Seven trials evaluated egg count and reported a wide range of
percent mean reductions among those not cured at one month
(86% to 100% versus 56% to 99.1%, four trials, 561 participants,
Analysis 10.4), three to four months (82% to 100% versus 42% to
100%, six trials, 791 participants, Analysis 10.4) and six months
(62.% to 100% versus 75% to 100%, four trials, 561 participants,
Analysis 10.4).
Adverse events
In five trials reporting adverse events, no serious events were
recorded. Dizziness and nausea were most commonly reported,
but these were transient and did not require additional interven-
tions (one trial, 482 participants, Table 9).
Analyses 11 and 12: Other oxamniquine dosing regimes
Nine additional trials compared 30 mg/kg oxamniquine with
higher and lower doses in Ethiopia (three trials), Zimbabwe (two
trials), Burundi (one trial), Nigeria (one trial), Sudan (one trial)
and Zambia (one trial).
Lower doses versus 30 mg/kg
Compared to 30 mg/kg, parasitological failure was higher with
15 mg/kg to 20 mg/kg oxamniquine at one month (RR 1.77,
95% CI 1.14 to 2.74, two trials, 230 participants), and at three
to four months (RR 2.16, 95% CI 1.40 to 3.32, four trials, 249
participants, Analysis 11.1).
At later follow-up times, no statistically significant difference were
demonstrated (six months: two trials, 179 participants; and 12
months: one trial, 95 participants, Analysis 11.1).
Higher doses versus 30 mg/kg
Compared to 30mg/kg, 60mg/kg oxamniquine resulted in signif-
icantly fewer parasitological failures at one month (RR 0.04, 95%
CI 0.01 to 0.26, two trials, 175 participants, Analysis 12.1), at
three to four months (RR 0.17, 95% CI 0.07 to 0.39, four trials,
265 participants, Analysis 12.2) and at six months (RR 0.17, 95%
CI 0.06 to 0.50, two trials, 157 participants, Analysis 12.3).
No statistically significant differences were seen between 50 mg/
kg and 30 mg/kg at one month (one trial, 36 participants, Anal-
ysis 12.1) or at three to four months (two trials, 53 participants,
Analysis 12.2).
Analysis 13: Praziquantel (40 mg/kg) versus oxamniquine
Eleven trials from different geographical locations directly com-
pared various doses of oxamniquine with praziquantel 40 mg/kg.
Dosing schedules commonly applied across different locations are
reported in Table 10. The most recent trial, from Sudan, was pub-
lished in 1990.
Parasitological failure
We did not identify statistically significant differences between
oxamniquine (at doses from 10 mg/kg to 60 mg/kg) and prazi-
quantel 40 mg/kg at one month (see Analysis 13.1). No difference
was demonstrable at three months between 25 to 30 mg/kg (three
trials, 319 participants), 40 mg/kg (one trial, 18 participants) or
50 to 60 mg/kg (one trial, 14 participants, Analysis 13.2). How-
ever, 10 to 20 mg/kg of oxamniquine did result in significantly
more failures (RR 3.42, 95% CI 1.10 to 10.61, two trials, 135
participants, Analysis 13.2).
In addition, therewere nodifferences betweenoxamniquine (lower
or higher dose) and praziquantel (40 mg/kg) at six months (nine
trials, 1167 participants, Analysis 13.3) or 12 months (one trial,
52 participants, Analysis 13.4).
Egg reduction
Three trials from Brazil, Ethiopia and Malawi compared oxam-
niquine 15, 20, 30, 40, and 50 mg/kg with praziquantel 40 mg/kg
and measured high percent egg reduction at one month (82.9%
to 100% for oxamniquine versus 90% to 92.8% for praziquantel,
two trials, 391 participants), three months (70.2% to 99.5% for
oxamniquine versus 70% to 100% for praziquantel, three trials,
440 participants), six months (32.5% to 97% for oxamniquine
versus 33.6% to 96.8% for praziquantel, three trials, 291 partic-
ipants), and 12 months (94% for oxamniquine versus 96% for
praziquantel, one trial, 91 participants, Analysis 13.5).
Adverse events
In five trials reporting fromBrazil, Ethiopia, Malawi, Saudi Arabia
and Tanzania that assessed adverse events, only two serious adverse
events were recorded (both with oxamniquine) in two trials: one
from a moderate endemicity setting in Ethiopia that used 30 mg/
kg in a split dose given the same day; and one trial from Saudi
Arabia that used a single dose of 25 mg/kg. No further differences
were observed in the number and type of adverse events between
oxamniquine and praziquantel although dizziness was recorded in
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excess with oxamniquine and abdominal pain with praziquantel
(Table 11).
Analysis 14: Myrrh (Mirazid) versus praziquantel
Parasitological failure
Myrhh (Mirazid) was tested in two trials at a single daily dose of
300mg for three days, and almost all failed treatment at three to six
weeks (RR 4.08, 95% CI 2.87 to 5.78, 236 participants, Analysis
14.1). Consequently, further investigation of this compound was
abandoned.
Egg reduction rate
There were only small reductions in reported percent geometric
mean egg reduction in these two studies, but they were not clini-
cally important (Analysis 14.2).
Adverse events
No trial reports adverse events.
Section 2. Combination therapies
Analysis 15: Praziquantel plus artesunate versus
praziquantel alone
One trial conducted from 1999 to 2000 in a high endemicity
setting in Senegal evaluated artesunate plus praziquantel versus
praziquantel alone.
Parasitological failure
In this setting, parasitological failure at one month occurred in
50% of participants given praziquantel 40 mg/kg alone. The addi-
tion of artesunate 12 mg/kg given in a divided dose of 2.5 mg/kg
daily for five days resulted in a lower failure rate at one month but
this did not reach statistical significance (one trial, 75 participants,
Analysis 15.1). At three and six months no additional benefit with
artesunate plus praziquantel was seen.
Egg reduction
Geometric mean egg reductions appear lower with combination
treatment but tests of statistical significance were not reported,
and the clinical relevance of this finding are unclear (one trial, 75
participants, Analysis 15.4).
Adverse events
Adverse events were not reported.
Analysis 16: Praziquantel plus oxamniquine versus
praziquantel alone
Only one trial in a high endemicity setting in Brazil published in
1987 has evaluated oxamniquine plus praziquantel versus prazi-
quantel alone.
Parasitological failure
Compared to praziquantel alone (40 mg/kg in two divided doses
on one day), a combination of oxamniquine (7.5 mg/kg) plus
praziquantel (20 mg/kg) did not demonstrate any statistically sig-
nificant benefits at three, six or 12 months follow-up (one trial,
52 participants, Analysis 16.1).
Egg reduction
The combination treatment was associated with lower geometric
mean egg reductions at three, six and 12 months but tests of sta-
tistical significance were not reported (one trial, 52 participants,
Analysis 16.4).
Adverse events
These were not reported.
Analysis 17: Praziquantel (8 mg/kg) plus oxamniquine (4
mg/kg) versus praziquantel (20 mg/kg) plus oxamniquine (10
mg/kg)
One small trial of schoolchildren from a high endemicity setting
co-endemic for S. mansoni and S. haematobium in Zimbabwe in-
vestigated different oxamniquine and praziquantel dose combina-
tions.
Parasitological failure
Children aged seven to 16 years and excreting more than 100
eggs per gram of stool were included in this trial. Statistically
fewer failures were seen with the higher dose-combination at one
month (RR 6.30, 95%CI 1.60 to 24.75, one trial, 28 participants,
Analysis 17.1), but not at three months (one trial, 29 participants,
Analysis 17.2) or six months (one trial, 20 participants, Analysis
17.3).
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Egg reduction
The percentage egg reduction also appeared to be lower in those
receiving the higher dose combination but tests of statistical sig-
nificance were not reported (one trial, 59 participants, Analysis
17.4).
Adverse events
No serious adverse events were recorded and the incidence of non-
severe events did not differ between combinations. About 70% of
children reported abdominal discomfort but these were transient
and had resolved by the following day (Table 12).
Analysis 18: Praziquantel (15 mg/kg) plus oxamniquine (7.5
mg/kg) versus praziquantel (20 mg/kg) plus oxamniquine (10
mg/kg)
One trial in Zimbabwe investigated slightly higher oxamniquine
and praziquantel dose combinations. The included children had
to excrete more than 100 eggs per gram of stool.
Parasitological failure
A statistically significant difference was not demonstrated at one,
three and six months (one trial, 48 participants, Analysis 18.1,
Analysis 18.2, Analysis 18.3).
Egg reduction rate
Percent egg reductions were high at one, three and six months
(82% to 96.1% versus 66.3% to 96.6%, one trial, 59 participants,
Analysis 18.4).
Adverse events
No serious adverse events were recorded apart from one child who
reported dizziness immediately after treatment but required no
further treatment (Table 12).
Section 3. Do failure rates vary in children and adults?
Praziquantel
A subgroup analysis conducted in two studies fromBurundi raised
concern that parasitological failure following 40 mg/kg may be
higher in children than in adults. The frequency of parasitological
treatment failure was consistently higher in children than adults
at one, three, six, and 12 months, and this was also observed for
doses of 20 mg/kg and 30 mg/kg (see Table 13).
Oxamniquine
Similarly, a subgroup analysis of two studies from Burundi and
Sudan administering oxamniquine has shown a consistent pattern
of higher parasitological treatment failure in children than adults
at one to 12 months (see Table 14).
Subgroup analysis of treatment arms receiving 40 mg/kg in the
other included studies was not possible given the available data.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Oxamniquine 40 mg/kg for treating S. mansoni infection
Patient or population: People with S. mansoni infection
Settings: Endemic settings
Intervention: Oxamniquine 40 mg/kg
Outcomes Comparison Illustrative comparative risks1 (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Oxamniquine 40 mg/kg Comparator
Parasitological failure
at 1 month
versus placebo2 18 per 100 100 per 100
(66 to 100)
RR 8.74
(3.74 to 20.43)
82
(2 trials)
⊕⊕⊕©
moderate3,4
versus 20 mg/kg 18 per 100 68 per 100
(37 to 100)
RR 3.78
(2.05 to 6.99)
190
(2 trials)
⊕⊕©©
low3,5
versus 30 mg/kg 18 per 100 32 per 100
(21 to 50)
RR 1.78
(1.15 to 2.75)
268
(4 trials)
⊕⊕©©
low3,5
versus 60 mg/kg 18 per 100 8 per 100
(2 to 38)
RR 0.45
(0.09 to 2.11)
317
(4 trials)
⊕⊕©©
low3,5
*The basis for the assumed risk is given in the footnotes.
The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
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1 Treatment failure with oxamniquine 40 mg/kg ranged from 5% to 24% in the included studies. The risk given here is the median risk in
these studies and is given for illustrative purposes.
2 Parasitological failure for the comparison with placebo was only reported at three months.
3 Downgraded by 1 for serious risk of bias: These studies did not adequately describe any methods to reduce the risk of bias.
4 Only two small studies have assessed this comparison. However, due to the very large effect size we have not downgraded further for
indirectness or imprecision.
5 Downgraded by 1 for indirectness: These studies are either too few, too small, or too old to have full confidence that the results can be
generalized to widespread control of S. mansoni today.
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Praziquantel 40 mg/kg versus oxamniquine 40 mg/kg for treating S. mansoni infection
Patient or population: People with S. mansoni infection
Settings: Endemic settings
Intervention: Oxamniquine 40 mg/kg
Control: Praziquantel 40 mg/kg
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Praziquantel
40 mg/kg
Oxamniquine
40 mg/kg
Parasitological failure
at 1 month
50 per 100 20 per 100
(7 to 61)
RR 0.40
(0.13 to 1.22)
33
(1 trial)
⊕©©©
very low1,2,3
*The basis for the assumed risk is provided in footnotes.
The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Downgraded by 1 for serious risk of bias: This study did not adequately describe any methods to reduce the risk of bias.
2 Downgraded by 1 for indirectness: This single study is over 20 years old.
3 Downgraded by 1 for imprecision: This trial is underpowered to detect what might be important differences in effect.
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Artesunate (12 mg/kg) plus praziquantel (40 mg/kg) versus praziquantel (40 mg/kg) alone for treating S. mansoni infection
Patient or population: People with S. mansoni infection
Settings: Endemic settings
Intervention: Artesunate (12 mg/kg) plus praziquantel (40 mg/kg)
Control: Praziquantel (40 mg/kg)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Praziquantel Artesunate plus praziquantel
Parasitological failure
at 1 month
50 per 100 31 per 100
(17 to 55)
RR 0.62
(0.35 to 1.09)
75
(1 trial)
⊕©©©
very low1,2,3
*The basis for the assumed risk (eg the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the
comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Downgraded by 1 for serious risk of bias: This study did not adequately describe any methods to reduce the risk of bias.
2 Downgraded by 1 for indirectness: This is a single study and the result is not easily generalized.
3 Downgraded by 1 for imprecision: This trial is underpowered to detect what might be important differences in effect.
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D I S C U S S I O N
Summary of main results
Compared to placebo, praziquantel 40 mg/kg substantially re-
duced parasitological treatment failure at one month post-treat-
ment (moderate quality evidence). Compared to this standard dose,
lower doses of 20 mg/kg and 30 mg/kg were inferior (low quality
evidence); and higher doses, up to 60 mg/kg, have not shown any
advantage (moderate quality evidence).
Compared to placebo, oxamniquine 40 mg/kg substantially re-
duced parasitological treatment failure at three months (moderate
quality evidence). Lower doses than 40 mg/kg were inferior at one
month (low quality evidence), and higher doses such as 60 mg/kg
have not shown a consistent benefit (low quality evidence).
Ten trials compared oxamniquine at 20, 30 and 60 mg/kg with
praziquantel 40 mg/kg and did not show any convincing differ-
ences in failure rate and percent egg reduction. Only one small
study directly compared praziquantel 40mg/kg with oxamniquine
40 mg/kg and did not demonstrate a statistically significant dif-
ference in parasitological failure (very low quality evidence).
Combining praziquantel with artesunate has not been shown to
have benefits in terms of failure rate compared to praziquantel
alone at one month, three or six months (one trial, 75 participants,
very low quality evidence). Two trials have also compared combina-
tions of praziquantel and oxamniquine in different doses but did
not find statistically significant differences in failure rate.
Compared to 40 mg/kg, no dose effect was demonstrable for clin-
ical improvement with lower doses (20 and 30 mg/kg) of prazi-
quantel or oxamniquine in resolving abdominal pain, diarrhoea,
blood in stool, hepatomegaly, and splenomegaly at one, three, six,
and 12 months, or up to two years of follow-up. Adverse events
were not well reported but were mostly described as minor and
transient.
Overall completeness and applicability of
evidence
For praziquantel, the evidence presented is generally supportive
of the current WHO recommended dose of 40 mg/kg to treat
S. mansoni infection (WHO 2002). Parasitological cure as low as
57% has been reported in Kenya in the 1990s (Olds 1999 KEN),
and 52% in Senegal in 1993 (Guisse 1997 SEN). However, higher
efficacy has been seen in more recent trials; Tanzania (81%), Mau-
ritania (95%) and Brazil (92%) in 2006/2007 (Olliaro 2011 BRA;
Olliaro 2011 MRT; Olliaro 2011 TZA), and Uganda (87%) in
2003/2005 (Tweyongyere 2009 UGA). The lower cure rates from
the earlier studies could be expected from the high endemicities
where pre-treatment intensity of infection were very high (preva-
lence > 80%) compared to the recent studies (prevalence < 30%).
In such situations, even at 95% efficacy, a sufficient number of
surviving schistosomes would remain, causing sustained egg ex-
cretion in most of the treated participants (Danso-Appiah 2002).
Furthermore, as a result of intense transmission, most treated par-
ticipants might have acquired large numbers of new infections just
before treatment and as immature worms are less sensitive to praz-
iquantel most would have escaped drug action and developed into
egg-laying adult worms shortly after treatment to present as fail-
ures. The high diagnostic sensitivity (mostly duplicate slides from
two or more consecutive stool specimens) and lower dose of praz-
iquantel applied in the earlier studies (except Guisse 1997 SEN)
would have also contributed to the observed lower cure rates.
The results in this review appear to be generalizable elsewhere but it
should be noted that these trials excluded preschool children under
five years and concerns remain that this dosemay be less effective in
this group. This is because praziquantel works in synergy with host
immune status (Sabah 1986) and this is not yet fully developed
in very young children. A subgroup analysis conducted in two
studies from Burundi with praziquantel at 40 mg/kg and another
two studies from Burundi and Sudan with oxamniquine 40 mg/
kg raises concern as parasitological failure was consistently higher
in children than in adults at one to 12 months of follow-up. This
trend was also observed for doses of 20 mg/kg and 30 mg/kg for
both treatments, and a higher dose (60 mg/kg) for oxamniquine.
Higher doses than 40 mg/kg have been national policy in Brazil
since 1995: 60 mg/kg for children and 50 mg/kg for adolescents
and adults. We found little direct evidence from randomized con-
trolled trials to support or refute this as a policy. Only a single
trial from Brazil reported outcomes at one month and this failed
to show a statistically significant advantage with 60 mg/kg com-
pared to 40 mg/kg, and excluded children aged less than 10 years
(Olliaro 2011 BRA). Several further trials from Brazil have eval-
uated higher doses and longer regimens but these only reported
outcomes at six months or beyond. These do offer some limited
evidence that increasing the dose of praziquantel might have par-
asitological benefits.
There is no justification for using lower doses, even if potentially
effective in morbidity control, as sub-curative doses may eventu-
ally select for drug resistant parasites (Doenhoff 1998; Doenhoff
2008).
Praziquantel is known to be less effective on immature schisto-
somes than adult worms (Sabah 1986), and combination therapy
(with drugs with unrelatedmechanisms of action and targeting the
different developmental stages of the schistosomes), has potential
as a future control strategy. Potential partner drugs include oxam-
niquine and the artemisinin derivatives. Of these, the artemisinin
derivatives have been shown to be effective against immature schis-
tosomes in laboratory studies (Utzinger 2001; Utzinger 2002;
Utzinger 2003; Utzinger 2007), and there is some indirect evi-
dence for efficacy from non-randomized studies in urinary schis-
tosomiasis (De Clercq 2002; Inyang-Etoh 2004; Boulanger 2007;
Inyang-Etoh 2009), and from people with malaria co-infected S.
haematobium (Boulanger 2007). However, to date only a single
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trial has directly evaluated praziquantel plus artesunate and no ad-
ditional benefit was observed compared to praziquantel alone (De
Clercq 2000 SEN).
For oxamniquine, there is no current consensus on the optimal
dosing regimen and it has largely fallen out of use in favour of
praziquantel. Although the presented data are now more than 20
years old, and suffers some methodological problems, there is suf-
ficient evidence of its efficacy against S. mansoni to suggest that
it could be reinstated as an alternate treatment to decrease the
pressure on praziquantel. However, a limitation of oxamniquine
is that its effect is restricted to S. mansoni as this is the only species
possessing the enzyme which converts oxamniquine to its active
metabolite (Cioli 1995). It is therefore unsuitable for use in areas
where co-infection with S. haematobium is common.
The optimal dose of oxamniquine may also be 40 mg/kg but fur-
ther studies are required to confirm this, preferably in direct com-
parison with praziquantel, and trials should include and evaluate
the efficacy of this dose in young children.
Safety was under reported and inconsistently assessed in most of
these clinical trials. Furthermore, only the few studies comparing
the intervention versus placebo allow identification of potentially
drug-related events. From these few studies it is therefore not pos-
sible to provide a reliable account of treatment tolerability.
Quality of the evidence
The quality of evidence was assessed using the GRADE method-
ology and displayed in summary of findings (SOF) tables for the
main comparisons. The level of quality is judged on a 4-point
scale. High quality evidence implies that level of confidence in
the effect estimate is high and that further research is unnecessary.
Moderate quality evidence implies lower confidence in the result
and further research may have an important impact on the result.
Low and very low quality evidence reflect increasing uncertainty
in the result and a greater need for further research.
The evidence presented is generally considered to be of moderate
or lowquality due to concerns related to three key factors: i) the age
of the trials, with the majority more than 20 years old, ii) the poor
methodological reporting of many of these older trials, and iii) the
number and size of the trials being small and often underpowered
to reliably detect statistically significant differences. The specific
reasons for downgrading the quality of the evidence are given in
the footnotes to the SOF tables.
Potential biases in the review process
A few minor difficulties in extracting the data from the available
papers should be noted but these are unlikely to have introduced
major bias into this review. For three trials (Gryseels 1989a BDI;
Gryseels 1989b BDI; Gryseels 1989c BDI), data on parasitologi-
cal failure were obtained from figures and might not be the exact
estimates. One trial (Sukwa 1993 ZMB) actually reported reinfec-
tion rate but this is included in this review because this outcome is
similar to failure rate. The trial by Tweyongyere 2009 UGA was a
nested cohort study within a larger mother and baby cohort study
in which pregnant women found to be infected with S. mansoni
were randomized to receive praziquantel or placebo. Despite rep-
resenting a special population, this is not likely to affect the valid-
ity of the results.
Agreements and disagreements with other
studies or reviews
A non-Cochrane review compared praziquantel with placebo in
two studies in Brazil and showed slightly higher cure rate with
praziquantel (Liu 2011). The reliability of the evidence in this
review cannot be established given that the two studies that assessed
this outcome involved only 25 participants.
The effects of praziquantel and artesunate in urinary schistoso-
miasis due to S. haematobium have been evaluated in a separate
Cochrane review last published in 2008. Praziquantel was found
to be effective against S. haematobium with few adverse events, and
similarly to this review there was insufficient evidence for the use of
artesunate monotherapy or combination therapy (Danso-Appiah
2008).
Limitations in the design and methodology in schistosomiasis
trials identified during the earlier Cochrane review, and conse-
quent future research needs have also been reported elsewhere
(Danso-Appiah 2009).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The available evidence supports single dose praziquantel at 40mg/
kg as the standard treatment for S. mansoni infection as recom-
mended by the WHO.
Oxamniquine, a largely discarded alternative, appears efficacious
and production and distribution should continue to ease selective
pressure on praziquantel. However, its use should be limited to
areas without S. haematobium co-endemicity.
Implications for research
Further research is necessary to find the optimal dosing regimen of
praziquantel and oxamniquine in children under five years, given
the observational evidence that failure rates with 40 mg/kg may
be higher in this age-group.
Combination therapy, ideally with drugs with unrelated mecha-
nisms of action and targeting the different developmental stages
of the schistosomes in the human host should be pursued as an
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area for future research; for example; praziquantel plus oxam-
niquine, praziquantel plus mefloquine, and praziquantel plus an
artemisinin derivative.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Abdel Rahim 1988 SDN
Methods Length of follow-up: one, two, three and six months, with additional examination for
children at 8 months
Participants Number randomized: 296
Inclusion criteria: children and adults with S. mansoni infection
Exclusion criteria: not stated
Diagnostic criteria: modified Kato-Katz thick smear (three smears from a single stool
sample)
Interventions 1. Oxamniquine (60 mg/kg): 15 mg/kg twice daily for two days
2. Oxamniquine (40 mg/kg): 10 mg/kg twice daily for two days
3. Oxamniquine (20 mg/kg): 10 mg/kg twice daily for one day
Outcomes 1. Cure rate
2. Egg reduction rate
Notes Location: Sudan
Date of trial: not stated
Endemicity: high (prevalence 80%)
Communities studied: not stated
Brand of drug: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’Patients were stratified according to age,
sex and intensity, and randomly allocated
to one of three groups’, no further details
given
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk None described
Incomplete outcome data (attrition bias)
All outcomes
High risk Attrition did not show a particular trend,
but high > 20%
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No other bias identified
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Al Aska 1990 SAU
Methods Length of follow-up: three and six months
Participants Number randomized: 200
Inclusion criteria: patients aged 10 to 63 years (mean: 26 years) with chronic S. mansoni
infection with no previous treatment history
Exclusion criteria: not stated
Diagnostic criteria: Kato-Katz thick smear, three consecutive stools plus rectal biopsy,
infection intensity expressed as geometric mean egg per gram of stool (EPG)
Interventions 1. Praziquantel (40 mg/kg x 1)
2. Oxamniquine (25 mg/kg x 1)
One arm consisting of patients with S. haematobium was excluded from this review
Outcomes 1. Failure rate
2. Adverse events
Notes Location: Saudi Arabia
Date of trial: not stated
Endemicity: hospital setting
Communities studied: N/A; hospital setting
Brand of drug: not stated
Proctoscopy was done in those patients who were suspected of having schistosomiasis,
but in whom frequent stool examination yielded negative findings. Three rectal spec-
imens obtained during proctoscopy were placed between slides and examined under a
microscope. The diagnosis was positive if living ova were seen
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as ’randomized’, no further de-
tails given
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk None described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not reported
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No other bias identified
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Ayele 1984 ETH
Methods Length of follow-up: three months
Participants Number randomized: 65
Inclusion criteria: adolescents and adults aged over 15 years with a geometric mean of
200 EPG or above
Exclusion criteria: subjects who had a history of seizure disorder, had received antis-
chistosomal treatment in the last six months or had received any other drugs or were
pregnant or lactating
Diagnostic criteria: modified Kato-Katz thick smear (quantity not stated)
Interventions 1. Oxamniquine (60 mg/kg): 15 mg/kg twice daily for two days
2. Oxamniquine (40 mg/kg): 10 mg/kg twice daily for two days
3. Oxamniquine (30 mg/kg): 15 mg/kg twice in one day
4. Placebo
Outcomes 1. Cure rate
2. Egg reduction rate
3. Adverse events
Notes Location: Ethiopia
Date of trial: not stated
Endemicity: high (prevalence not stated)
Communities studied: not stated
Brand of drug: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as ’patients were allocated randomly’,
no further details given
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk None described
Incomplete outcome data (attrition bias)
All outcomes
High risk Sample size small < 20 participants in each arm:
attrition same across arms, but high ( > 20%)
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No other bias identified
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Ayele 1986 ETH
Methods Length of follow-up: four months
Participants Number randomized: 162
Inclusion criteria: children below 15 years of age (specific age range not stated)
Exclusion criteria: subjects with a history of seizure disorder, geometric mean of less than
200 EPG or who had received antischistosomal treatment in the previous six months
Diagnostic criteria: modified Kato-Katz smear method (three daily consecutive stool
samples)
Interventions 1. Oxamniquine (60 mg/kg): 15 mg/kg twice daily for two days
2. Oxamniquine (40 mg/kg): 20 mg/kg twice for one day
3. Oxamniquine (30 mg/kg): 15 mg/kg twice for one day
4. Placebo
Outcomes 1. Cure rate
2. Egg reduction rate
3. Adverse events
Notes Location: Ethiopia
Date of trial: 1984
Endemicity: high (prevalence not stated)
Communities studied: one
Brand of drug: Vansil
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’Each subject selected for inclusion in the study
was randomly assigned to one of four treatment
groups’, no further details given
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk All laboratory technicians were unaware of the dif-
ferent treatment groups
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses recorded up to six months follow-up
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No other bias identified
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Barakat 2005 EGY
Methods Length of follow-up: three and six weeks
Participants Number randomized: 104
Inclusion criteria: S. mansoni-positive individuals from a whole population
Exclusion criteria: not stated
Diagnostic criteria: two consecutive stools (duplicate Kato-Katz thick smear, each 41.7
mg)
Interventions 1. Myrrh given in the form of Mirazid capsules (two capsules in three consecutive days
which was repeated at three weeks time) regardless of weight or age of the patient as
recommended by the manufacturer
2. Praziquantel (40 mg/kg, two doses given at a three-week interval)
Outcomes 1. Cure rate
2. Egg reduction rate
Notes Location: Egypt
Date of trial: not stated
Endemicity: moderate (prevalence 14.5%)
Communities studied: one
Study was conducted during the transmission period
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’Of the infected person, 104 individuals
were randomized in two groups, the first for
myrrh and the second for praziquantel, the
characteristics of the two groups being com-
parable’, no further details given
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk None described
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses recorded, used ITT analysis
Selective reporting (reporting bias) Low risk No evidence of selecting reporting
Other bias Low risk No other bias identified
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Botros 2005 EGY
Methods Length of follow-up: four weeks for children and five to six weeks for adults
Participants Number randomized: 271 including 30 who did not comply fully with the treatment
protocol
Inclusion criteria: children and adolescent aged 12 to 18 years and adults aged over 18
years who had S. mansoni eggs in their stool
Exclusion criteria: not stated
Diagnostic criteria: standard Kato-Katz thick smear (one stool, 4 slides pre-treatment),
but three consecutive stools and 4 slides per stool (post-treatment): 41.7 mg of stool
Interventions 1. Myrrh (Mirazid; 300 mg/day x 3 days)
2. Praziquantel (40 mg/kg x 1)
Outcomes 1. Cure rate
2. Egg reduction rate
Notes Location: Egypt
Date of trial: not stated
Endemicity: moderate (prevalence not stated)
Communities studied: one
Study was conducted during period of low transmission
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’All positive eligible subjects were strati-
fied into low, moderate and heavy infection
strata. Each stratum was then randomly as-
signed into twogroups.One group received
Mirazid while the second group received
praziquantel’, no further details given
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk ’All parasitologists who examined the
slides, the technicians who processed them,
the clinicians who performed rectal snips,
and those responsible for data entry were
blinded to the type of treatment given’
Incomplete outcome data (attrition bias)
All outcomes
High risk Losses were high: 11/66 (16.7%) in myrrh
versus 19/51 (37.3%) in praziquantel
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No other bias identified
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Branchini 1982 BRA
Methods Length of follow-up: six months
Participants Number randomized: 101
Inclusion criteria: patients aged 10 to 65 years with chronic intestinal S. mansoni infection
Exclusion criteria: not stated
Diagnostic criteria: three consecutive stool (3 slides each) from Kato-Katz and sponta-
neous sedimentation methods. EPG expressed as geometric mean
Interventions 1. Praziquantel (45.4 mg/kg x 1)
2. Oxamniquine (13.8 mg/kg x 1)
3. Placebo
Outcomes 1. Cure rate
2. Adverse events
Notes Location: Brazil
Date of trial: not stated
Endemicity: hospital setting
Communities studied: N/A; hospital setting
Brand of drug: not stated
Chronic schistosomiasis cases were included in the trial
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’Patients were randomly allocated into three parallel
groups, one received praziquantel, one oxamniquine,
and one placebo’
Allocation concealment (selection bias) Low risk The trial was double-blindplacebo control trial. ’The
drugs were administered as a single oral dose in con-
formity to a double-blind technique’
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind placebo controlled trial
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Attrition not reported
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No other bias identified
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Creasey 1986 ZWE
Methods Length of follow-up: one, three and six months
Participants Number randomized: 107 (59 participants were randomized into S. mansoni treatment
and were included in this review)
Inclusion criteria: schoolchildren aged 7 to 16 years with both S. mansoni and S. haema-
tobium infections
Exclusion criteria: not stated
Diagnostic criteria: Kato-Katz thick smear (three consecutive stools)
Interventions 1. Praziquantel (8 mg/kg x 1) plus oxamniquine (4 mg/kg x 1)
2. Praziquantel (15 mg/kg x 1) plus oxamniquine (7.5 mg/kg x 1)
3. Praziquantel (20 mg/kg x 1) plus oxamniquine (10 mg/kg x 1)
Three arms consisting of 58 participants infected with S. haematobium was excluded
Outcomes 1. Cure rate
2. Egg reduction rate
3. Adverse events
Notes Location: Zimbabwe
Date of trial: not stated
Endemicity: high (prevalence not stated)
Communities studied: one
Brand of drug: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’The children were randomly assigned to
three groups of 10, 30 and 19, respectively,
and the combination drug administered at
three dosage levels’, no further details given
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk None described
Incomplete outcome data (attrition bias)
All outcomes
High risk Losses were differential: very low in some
arms but high reaching >40% in other arms
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No other bias identified
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da Cunha 1986 BRA
Methods Length of follow-up: six months
Participants Number randomized: 58
Inclusion criteria: adolescent and adult patients aged 15 to 55 years with chronic S.
mansoni infection
Exclusion criteria: pregnant and lactating women, with associated kidney, lung, liver
or heart disease, acute or sever chronic illness as well marked anaemia or nutritional
deficiencies
Diagnostic criteria: Quantitative oogram for the estimation of number of viable eggs per
gram of tissue found in rectal mucosa biopsies
Interventions 1. Praziquantel (65 mg/kg x 1)
2. Oxamniquine (18 mg/kg x 1)
Outcomes 1. Adverse events
2. Cure rate
3. Egg reduction rate
Notes Location: Brazil
Date of trial: not stated
Endemicity: N/A; hospital setting
Communities studied: N/A; hospital setting
Brand of drug: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’Following parallel group design, the patients upon
entering the trial were allocated into one of the
two groups distributed according to age, sex, body
weight, clinical form of the disease and worm bur-
den’
Allocation concealment (selection bias) Low risk ’The two drugs were dispensed in individually coded
bottles and presented in capsules of identical appear-
ance but containing different dosages. The double-
blind code was provided prior to the beginning of
the study within sealed envelopes, for each case, to
be opened only at the end of the trial’
Blinding (performance bias and detection
bias)
All outcomes
Low risk ’Patients were treated in accordance with double-
blind administration’
Incomplete outcome data (attrition bias)
All outcomes
Low risk Number of participants across arms very small; 3/27
in the praziquantel arm and 5/27 in the oxamniquine
arm were lost to follow-up at 6 months
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da Cunha 1986 BRA (Continued)
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Unclear risk No other bias identified, but low numbers were in-
cluded in the study
da Cunha 1987 BRA
Methods Length of follow-up: two, four and six months, but only six months follow-up was used
in the analysis
Participants Number randomized: 80
Inclusion criteria: adolescent and adults patients aged 15 to 55 years with no previous
antischistosomal treatment who were infected with S. mansoni
Exclusion criteria: children, elderly patients, patients with concomitant acute or serious
chronic disease, severe anaemia or nutritional deficiency, pregnant and lactating women,
with associated kidney, lung, liver or heart disease
Diagnostic criteria: Quantitative oogram for the estimation of number of viable eggs per
gram of tissue found in rectal mucosa biopsies
Interventions 1. Praziquantel (60 mg/kg, given as 30 mg/kg x 2 for 1 day)
2. Praziquantel (120 mg/kg, given as 30 mg/kg x 2 for 2 days)
3. Praziquantel (180 mg/kg, given as 30 mg/kg x 2 for 3 days)
4. Praziquantel (180 mg/kg, given as 30 mg/kg x 1 for 6 days)
Divided doses were given 4 hours apart
Outcomes 1. Adverse events
2. Cure rate
3. Egg reduction rate
Notes Location: Brazil
Date of trial: not stated
Endemicity: N/A; hospital setting
Communities studied: N/A; hospital setting
Brand: not stated
All patients lived away from endemic areas
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’Patients were randomly allocated into four
groups with equal number of cases...’ The
authors make reference to their earlier trial
which used parallel group design
Allocation concealment (selection bias) Low risk Not explicitly stated, but the authors make
reference to their earlier parallel double-
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da Cunha 1987 BRA (Continued)
blind trial where the two drugs were dis-
pensed in individually coded bottles and
presented in capsules of identical appear-
ance but containing different dosages. The
double-blind code was provided prior to
the beginning of the study within sealed
envelopes, for each case, to be opened only
at the end of the trial’
Blinding (performance bias and detection
bias)
All outcomes
Low risk The authors make reference to their earlier
trial where they stated ’Patientswere treated
in accordance with double-blind adminis-
tration’
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not reported
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No other bias identified
da Silva 1986 BRA
Methods Length of follow-up: one, three and six months
Participants Number randomized: 120
Inclusion criteria: patients with chronic intestinal or hepato-intestinal S. mansoni infec-
tion aged over 14 years
Exclusion criteria: clinical form (hepatosplenic cases), patients with associated acute
and/or serious disease, pregnant women and those treated in the past six months with
antischistosomal drug
Diagnostic criteria: Kato-Katz smear (three slides of three consecutive stools)
Interventions 1. Oxamniquine (15 mg/kg)
2. Praziquantel (55 mg/kg x 1)
Outcomes 1. Adverse events
2. Cure rate
3. Egg reduction rate
Notes Location: Brazil
Date of trial: not stated
Endemicity: N/A; hospital setting
Communities studied: N/A; hospital setting
Brand: not stated
Efficacy assessment was based on only those who finished three negative post treatment
parasitological follow-up (one, three and six months)
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da Silva 1986 BRA (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’The patients were randomly allocated into
two groups having an equal number of
cases’, no further details given
Allocation concealment (selection bias) Unclear risk ’Both drugs were given in a single oral dose
in accordance with a double-blind tech-
nique’, no further details given
Blinding (performance bias and detection
bias)
All outcomes
Low risk ’Double-blind clinical trial’
Incomplete outcome data (attrition bias)
All outcomes
High risk Losses did not differ across arms, but
around > 20% was high. ’Eefficacy was as-
sessed based on those who finished three
negative post treatment parasitological fol-
low-ups (1, 3 and 6 months)’
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No other bias identified
de Clarke 1976a ZWE
Methods Length of follow-up: four months
Participants Number randomized: 30
Inclusion criteria: individuals aged over 5 years who presented with S. mansoni infection
Exclusion criteria: not stated
Diagnostic criteria: two stools on two consecutive days using the following threemethods:
sedimentation, hatching and Visser and Pitchford method
Interventions 1. Oxamniquine (15 mg/kg x 1)
2. Oxamniquine (20 mg/kg x 1)
Outcomes 1. Failure rate
2. Egg reduction rate
Notes Location: Zimbabwe
Date of trial: 1972 to 1975
Endemicity: N/A; referral cases
Communities studied: patients referred to the Blair Research Laboratory
Brand: not stated
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de Clarke 1976a ZWE (Continued)
As far as possible those infected with both S. haematobium and S. mansoni were included
in the study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as ’randomized’, no further details given
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk None described
Incomplete outcome data (attrition bias)
All outcomes
High risk Sample size very small across arms ≤ 15 and attri-
tion was high reaching 33%
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Unclear risk Used very sensitive diagnostic technique: two stools
on two consecutive days using a combination of
sedimentation, hatching and Visser and Pitchford
method. Pretreatment diagnostic sensitivity dif-
fered at one time point
de Clarke 1976b ZWE
Methods Length of follow-up: four months
Participants Number randomized: 26
Inclusion criteria: individuals aged over 5 years who presented with S. mansoni infection
Exclusion criteria: not stated
Diagnostic criteria: two stools on two consecutive days using the following threemethods:
sedimentation, hatching and Visser and Pitchford method
Interventions 1. Oxamniquine (20 mg/kg): 5 x 2 mg/kg daily for 2 days
2. Oxamniquine (30 mg/kg): 7.5 mg/kg x 2 daily for 2 days
3. Oxamniquine (40 mg/kg): 10 x 2 mg/kg daily for 2 days
Outcomes 1. Failure rate
2. Egg reduction rate
Notes Location: Zimbabwe
Date of trial: not stated
Endemicity: N/A; referral cases
Communities studied: patients referred to the Blair Research Laboratory
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de Clarke 1976b ZWE (Continued)
Brand: not stated
As far as possible those infected with both S. haematobium and S. mansoni were included
in the study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as ’randomized’, no further details given
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk None described
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses recorded
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No other bias identified
de Clarke 1976c ZWE
Methods Length of follow-up: four months
Participants Number randomized: 30
Inclusion criteria: individuals aged over 5 years who presented with S. mansoni infection
Exclusion criteria: not stated
Diagnostic criteria: two stools on two consecutive days using the following threemethods:
sedimentation, hatching and Visser and Pitchford method
Interventions 1. Oxamniquine (60 mg/kg): 15 x 2 mg/kg daily for 2 days
2. Oxamniquine (50 mg/kg): 12.5 x 2 mg/kg daily for 2 days
Outcomes 1. Failure rate
2. Egg reduction rate
Notes Location: Zimbabwe
Date of trial: not stated
Endemicity: N/A; referral cases
Communities studied: patients referred to the Blair Research Laboratory
Brand: not stated
As far as possible those infected with both S. haematobium and S. mansoni were included
in the study
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de Clarke 1976c ZWE (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as ’randomized’, no further details given
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk None described
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses recorded
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Unclear risk Used very sensitive diagnostic technique: ’two
stools on two consecutive days using a combination
of sedimentation, hatching and Visser and Pitch-
ford method’. Pretreatment diagnostic sensitivity
differed at one time point
de Clarke 1976d ZWE
Methods Length of follow-up: four months
Participants Number randomized: 45
Inclusion criteria: individuals aged over 5 years who presented with S. mansoni infection
Exclusion criteria: not stated
Diagnostic criteria: two stools on two consecutive days using the following threemethods:
sedimentation, hatching and Visser and Pitchford method
Interventions 1. Oxamniquine (50 mg/kg): 12.5 x 2 mg/kg daily for 2 days
2. Oxamniquine (30 mg/kg): 15 x 2 mg/kg in a single day
3. Oxamniquine (30 mg/kg): 10 x 3 mg/kg in a single day
Outcomes 1. Failure rate
2. Egg reduction rate
Notes Location: Zimbabwe
Date of trial: not stated
Endemicity: N/A; referral cases
Communities studied: patients referred to the Blair Research Laboratory
Brand: not stated
As far as possible those infected with both S. haematobium and S. mansoni were included
in the study
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de Clarke 1976d ZWE (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as ’randomized’, no further details given
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk None described
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses recorded
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Unclear risk Used very sensitive diagnostic technique: ’two
stools on two consecutive days using a combination
of sedimentation, hatching and Visser and Pitch-
ford method’. Pretreatment diagnostic sensitivity
differed at one time point
De Clercq 2000 SEN
Methods Length of follow-up: five, 12 and 24 weeks
Participants Number randomized: 110
Inclusion criteria: individuals positive for S. mansoni
Exclusion criteria: children under 1 year, pregnant women and severely ill patients were
excluded if they were receiving medication for any other infection or if they had received
medication for schistosomiasis within the preceding six months
Diagnostic criteria: single stool (duplicate Kato-Katz thick smear)
Interventions 1. Artesunate (12 mg/kg): 2.4 mg/kg x 5
2. Praziquantel (40 mg/kg x 1)
3. Artesunate (12 mg/kg: 2.4 mg/kg x 5) plus praziquantel (40 mg/kg x 1)
Outcomes 1. Cure rate
2. Egg reduction rate
Notes Location: Senegal
Date of trial: 1999 to 2000
Endemicity: high (prevalence 60%)
Communities studied: one
Brand: not stated
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De Clercq 2000 SEN (Continued)
Compliance with the 5-day regimen of artesunate was excellent; all completed this regime
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’Patients were allocated to one of three
groups’, no further details given
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk None described
Incomplete outcome data (attrition bias)
All outcomes
High risk No losses at one month, but losses were
high in the artesunate arm (reaching 25%)
at six months compared to 5% in the praz-
iquantel arm
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No other bias identified
de Jonge 1990 SDN
Methods Length of follow-up: one month
Participants Number randomized: 182 (123 participants were included in the analysis)
Inclusion criteria: boys aged 6 to 13 years having both S. haematobium and S. mansoni
infections
Exclusion criteria: not stated
Diagnostic criteria: three consecutive stools and three slides each of modified Kato-Katz
thick smear technique (Teesdale and Amin). Five Kato-Katz thick smears of 40 mg each
were examined daily
Interventions 1. Praziquantel (40 mg/kg x 1)
2. Oxamniquine (60 mg/kg x 1)
A third arm (38 patients) that received metrifonate and a fourth arm of 21 patients
(control) selected from a nearby village with low prevalence where children without
infection were given multivitamin preparation to act as non-randomized control group,
were excluded from this analysis
Outcomes 1. Cure rate
2. Egg reduction
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de Jonge 1990 SDN (Continued)
Notes Location: Sudan
Date of trial: not stated
Endemicity: high (prevalence not stated)
Communities studied: one
Brand: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’The patients were randomly divided into four
groups’, no further details given
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk None described
Incomplete outcome data (attrition bias)
All outcomes
High risk Losses were similar at one month, but different at
three months: 27% in the 40 mg/kg praziquantel
arm versus 17% in the 60mg/kg in the oxamniquine
arm
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Unclear risk Only boys aged 6 years were included in the trial,
but no reason given
Fernandes 1986 BRA
Methods Length of follow-up: six months
Participants Number randomized: 120
Inclusion criteria: patients aged 15 to 72 years excreting more than 100 to 2,500 EPG
of S. mansoni were included
Exclusion criteria: pregnant or lactating women, weak patients or those with cardiac,
renal or hepatic insufficiency, and patients with other acute or more severe illnesses than
schistosomiasis
Diagnostic criteria: three consecutive stools using Kato-Katz thick smear
Interventions 1. Praziquantel (70 mg/kg x 1)
2. Praziquantel (35 mg/kg x 2)
3. Oxamniquine (15 mg/kg x 1)
Outcomes 1. Cure rate
2. Adverse events
3. Egg reduction rate
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Fernandes 1986 BRA (Continued)
Notes Location: Brazil
Date of trial: not stated
Endemicity: N/A; outpatient setting
Communities studied: N/A; hospital setting
Chronic schistosomiasis cases were included in the trial
Adverse events were evaluated during a 6 to 8 hour period after administration of the
drugs, based on clinical observations by the researchers
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’Patients were assigned randomly to one of three
groups’, no further details given
Allocation concealment (selection bias) High risk ’Nomethods were taken to conceal allocation of par-
ticipants to the treatment groups’
Blinding (performance bias and detection
bias)
All outcomes
High risk Outcomes assessment was not blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not reported
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Unclear risk Only patients with moderate to heavy infection were
included in the study
Ferrari 2003 BRA
Methods Length of follow-up: six months
Participants Number randomized: 106
Inclusion criteria: patients aged 12 to 56 years attending the hospital found to have S.
mansoni infection
Exclusion criteria: children of pre-school age, the aged, pregnant and lactating women,
suckling infants, patients with acute or chronic severe concomitant diseases, patients
with hepatosplenic form of schistosomiasis and those whose water contact put them at
risk for reinfection
Diagnostic criteria: Kato-Katz thick smear (three consecutive stools) in addition to quan-
titative oogram (rectal biopsies)
Interventions 1. Praziquantel (60 mg/kg per day for 3 consecutive days)
2. Oxamniquine (10 mg/kg x 1, followed by starch in days 2 and 3)
3. Placebo (starch)
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Ferrari 2003 BRA (Continued)
Outcomes 1. Cure rate
Notes Location: Brazil
Date of trial: not stated
Endemicity: N/A; hospital setting
Communities studied: N/A; hospital setting
Brand: not stated
Very sensitive diagnosis was applied. Efficacy was assessed as patient testing negative after
treatment and remaining negative for up to six months
All patients were advised to stay away from the transmission foci, and they reported
doing so
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’Patients were randomly allocated to one of three
groups’, no further details given
Allocation concealment (selection bias) Low risk The identity of each treatment was kept in a sealed
envelope and the capsules were identical in shape and
appearance as the active drugs
Blinding (performance bias and detection
bias)
All outcomes
Low risk Triple masked randomized controlled trial. ’The in-
vestigators were blind to which patients were given
which treatment, the identity of each was kept in a
sealed envelope’
Incomplete outcome data (attrition bias)
All outcomes
High risk Losses were high: 10/36 (28%) in the praziquantel
arm, 3/34 (9%) in the oxamniquine and 7/36 (19%)
in the placebo arm
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No other bias identified
Gryseels 1989a BDI
Methods Length of follow-up: 1.5, three, six, 12 and 24 months
Participants Number randomized: 163 children and 267 adults
Inclusion criteria: all individuals excreting eggs for S. mansoni in their stool
Exclusion criteria: those with contraindication
Diagnostic criteria: duplicate Kato-Katz thick smear (28 mg) each from one stool
Interventions 1. Oxamniquine (40 mg/kg x 1)
2. Oxamniquine (30 mg/kg x 1)
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Gryseels 1989a BDI (Continued)
3. Oxamniquine (20 mg/kg x 1)
Outcomes 1. Failure rate
2. Resolution of abdominal pain
3. Resolution of diarrhoea
4. Resolution of blood in stool
5. Resolution of hepatomegaly
6. Resolution of splenomegaly
Notes Location: Burundi
Date of trial: 1983 to 1986
Endemicity: high (prevalence 66%)
Communities studied: one
Brand: not stated
Hepatomegaly was measured under the costal arch and splenomegaly was measured as
described by Hackett 1944
Children only were included in the efficacy analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’All patients excreting eggs of S. mansoni
were treated with one of the randomly al-
located schedules’, no further details given
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk None described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Number lost to follow-up not stated
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No other bias identified
Gryseels 1989b BDI
Methods Length of follow-up: 1.5, three, six, 12 and 24 months
Participants Number randomized: 299 children and 153 adults
Inclusion criteria: all individuals excreting eggs for S. mansoni in their stool
Exclusion criteria: those with contraindication
Diagnostic criteria: duplicate Kato-Katz thick smear (28 mg) each from one stool
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Gryseels 1989b BDI (Continued)
Interventions 1. Praziquantel (40 mg/kg x 1)
2. Praziquantel (30 mg/kg x 1)
3. Praziquantel (20 mg/kg x 1)
Outcomes 1. Failure rate
2. Resolution of abdominal pain
3. Resolution of diarrhoea
4. Resolution of blood in stool
5. Resolution of hepatomegaly
6. Resolution of splenomegaly
Notes Location: Burundi
Date of trial: 1983 to 1986
Endemicity: moderate (prevalence 38%)
Communities studied: one
Brand: not stated
Hepatomegaly was measured under the costal arch and splenomegaly was measured as
described by Hackett 1944
Children only were included in the efficacy analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’All patients excreting eggs of S. mansoni
were treated with one of the randomly al-
located schedules’, no further details given
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk None described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Number lost to follow-up not stated
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No other bias identified
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Gryseels 1989c BDI
Methods Length of follow-up: 1.5, three, six, 12 and 24 months
Participants Number randomized: 193 children and 125 adults
Inclusion criteria: all individuals excreting eggs for S. mansoni in their stool
Exclusion criteria: those with contraindication
Diagnostic criteria: duplicate Kato-Katz thick smear (28 mg) each from one stool
Interventions 1. Praziquantel (40 mg/kg x 1)
2. Praziquantel (30 mg/kg x 1)
Outcomes 1. Failure rate
2. Resolution of abdominal pain
3. Resolution of diarrhoea
4. Resolution of blood in stool
5. Resolution of hepatomegaly
6. Resolution of splenomegaly
Notes Location: Burundi
Date of trial: 1983 to 1986
Endemicity: moderate (prevalence 42%)
Communities studied: one
Brand: not stated
Hepatomegaly was measured under the costal arch and splenomegaly was measured as
described by Hackett 1944
Children only were included in the efficacy analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk All patients excreting eggs of S. mansoni
were treated with one of the randomly al-
located schedules’, no further details given
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk None described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Number lost to follow-up not stated
Selective reporting (reporting bias) Low risk Noevidence of selective reporting
Other bias Low risk No other bias identified
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Guisse 1997 SEN
Methods Length of follow-up: three, six and 21 weeks
Participants Number randomized: 130
Inclusion criteria: children infected with S. mansoni with no previous history of antis-
chistosomal treatment
Exclusion criteria: not stated
Diagnostic criteria: two consecutive stools (duplicate Kato-Katz thick smear, 25 mg
Interventions 1. Praziquantel (40 mg/kg x 1)
2. Praziquantel (30 mg/kg x 2)
Outcomes 1. Cure rate
2. Egg reduction rate
3. Adverse events
Notes Location: Senegal
Date of trial: 1993
Endemicity: high (100%)
Communities studied: one
Brand: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’Patients with no history of previous treat-
ment with praziquantel, were selected and
randomly allocated into two treatment
groups’, no further details given
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk None reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not reported
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No other bias identified
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Gupta 1984 ZMB
Methods Length of follow-up: one, two, three and six months
Participants Number randomized: 60
Inclusion criteria: adults patient with S. mansoni infection
Exclusion criteria: pregnant and lactating women, patients with concurrent systematic
diseases and those who received antischistosomal treatment within one month before
the trial
Diagnostic criteria: Stoll/Hauseer’s method
Interventions 1. Oxamniquine (60 mg/kg): 15 mg/kg twice daily for two days
2. Oxamniquine (40 mg/kg): 10 mg/kg twice daily for two days
3. Oxamniquine (30 mg/kg): 15 mg/kg twice daily for one day
Outcomes 1. Cure rate
2. Egg reduction rate
3. Adverse events
Notes Location: Zambia
Date of trial: March 1980 to 1982
Endemicity: patients visiting Lusaka hospital
Communities studied: not stated
Brand: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Patients were randomly allocated to three
oxamniquine groups’, no further details
given
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk None described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Sample size small, losses not reported
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Unclear risk No other bias identified
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Homeida 1989 SDN
Methods Length of follow-up: 1.5 and six months
Participants Number randomized: 885
Inclusion criteria: individuals who were positive for S. mansoni
Exclusion criteria: pregnant women, patients who vomited the drug within half an hour
or those who reported to have received antischistosomal treatment within the previous
6 months
Diagnostic criteria: modified Kato-Katz thick smear
Interventions 1. Praziquantel (40 mg/kg x 1): Biltricide
2. Praziquantel (40 mg/kg x 1): Distocide
Outcomes 1. Cure rate
2. Egg reduction rate
3. Adverse events
Notes Location: Sudan
Date of trial: not stated
Endemicity: high (prevalence not stated)
Communities studied: one
Brand: Biltricide and Distocide
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’1050 infected individuals who agreed to
take part were randomly allocated to biltri-
cide or distocide’, no further details given
Allocation concealment (selection bias) Unclear risk ’Tablets were similar in appearance and were
dispensed by a doctor’, no further details
given
Blinding (performance bias and detection
bias)
All outcomes
Low risk Outcome assessor of side effects blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk There was differential loss of participants
to follow-up at six months: Biltricide (7%)
versus Distocide (12%), but the sample was
large (> 400 patients in each arm) and this is
not likely to introduce bias into the results
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No other bias identified
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Ibrahim 1980 SDN
Methods Length of follow-up: one, two and three months
Participants Number randomized: 129 (89 participants were included in the analysis)
Inclusion criteria: all university students attending the university hospital found to have
S. mansoni infection
Exclusion criteria: only one patient who had chronic valvular heart disease was excluded
Diagnostic criteria: modified Kato-Katz thick smear (three daily stool examinations)
Interventions 1. Oxamniquine (60 mg/kg): 15 mg/kg twice daily for two days
2. Oxamniquine (40 mg/kg): 10 mg/kg twice daily for two days
One arm of 40 participants with no current or previous schistosomiasis was excluded
Outcomes 1. Cure rate
2. Egg reduction rate
Notes Location: Sudan
Date of trial: not stated
Endemicity: low (prevalence not stated)
Communities studied: university students on campus
Brand: Vansil
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as ’Double-blind random allo-
cation’, no further details given
Allocation concealment (selection bias) Low risk Double-blind random allocation
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind random allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses low < 10% and did not differ across
arms
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No other bias identified
Jaoko 1996 KEN
Methods Length of follow-up: 24 hours
Participants Number randomized: 436
Inclusion criteria: schoolchildren aged 7 to 16 years infected with S. mansoni
Exclusion criteria: children who were on medication for whatever reason
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Jaoko 1996 KEN (Continued)
Diagnostic criteria: duplicate modified Kato-Katz thick smear
Interventions 1. Praziquantel (40 mg/kg x 1)
2. Placebo
Outcomes 1. Adverse events
Notes Location: Kenya
Date of trial: not stated
Endemicity: high (prevalence > 83%)
Communities studied: one
Brand: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as ’patients were randomly assigned to treat-
ment’, no further details given
Allocation concealment (selection bias) Low risk Placebo controlled trial
Blinding (performance bias and detection
bias)
All outcomes
Low risk Placebo controlled trial
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not reported
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No other bias identified
Kardaman 1983 SDN
Methods Length of follow-up: one month
Participants Number randomized: 350
Inclusion criteria: all schoolchildren who provided two stool samples positive for S.
mansoni or two urine samples positive for S. haematobium were included
Exclusion criteria: children aged < 6 years, patients with contraindications, patients with
serious or acute disease, those who had received antischistosomal treatment within the
preceding six months, pregnant and lactating women
Diagnostic criteria: single stool (three slides) from locally developed thick-smearmethod,
Teesdale & Amin (Teesdale 1976)
Interventions 1. Praziquantel (40 mg/kg x 1)
2. Praziquantel (20 mg/kg x 2) given 4 to 6 hours apart
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Kardaman 1983 SDN (Continued)
Outcomes 1. Failure rate
2. Adverse events
Notes Location: Sudan
Date of trial: December 1979 to March 1980
Endemicity: moderate (prevalence not stated)
Communities studied: one
Brand: Biltricide
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’In one Arab village, 350 patients with S. mansoni
were randomly assigned to one of two treatment
groups’, no further details given
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk None described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses were 12% in the single dose (40 mg/kg) ver-
sus 9% in the divided dose (20 mg/kg x 2) of prazi-
quantel
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No other bias identified
Kardaman 1985 SDN
Methods Length of follow-up: five weeks and three months
Participants Number randomized: 237, but only 220 received treatment
Inclusion criteria: children aged 7 to 11 years who provided two positive stool samples
for S. mansoni and two positive urine samples for S. haematobium
Exclusion criteria: children were excluded if they were receiving medication for any other
infection or if they had received medication for schistosomiasis within the preceding six
months
Diagnostic criteria: locally developed thick-smear method, Teesdale & Amin (Teesdale
1976)
Interventions 1. Praziquantel (40 mg/kg x 1)
2. Praziquantel (20 mg/kg x 2) given 4 to 6 hours apart
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Kardaman 1985 SDN (Continued)
Outcomes 1. Failure rate
2. Adverse events
Notes Location: Sudan
Date of trial: not stated
Endemicity: high (prevalence not stated)
Communities studied: not stated
Brand: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’All children who provided two positive
stool were then randomly assigned to take
either a single 40 mg/ kg dose a divided
dose’, no further details given
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk None described
Incomplete outcome data (attrition bias)
All outcomes
High risk Randomized 237 participants but 220 re-
ceived treatment. Losses were < 10%
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No other bias identified
Katz 1979a BRA
Methods Length of follow-up: six and 12 months
Participants Number randomized: 55
Inclusion criteria: male patients aged 20 to 48 years from the military police of Minas
Gerais who were excreting > 100 EPG of S. mansoni (calculated from a minimum of two
stool samples)
Exclusion criteria: not stated
Diagnostic criteria: Kato-Katz thick smear (plus hatching test), three consecutive stool
(two slides from each stool plus three hatching tests on each stool); EPG expressed as
geometric mean
Interventions 1. Praziquantel (20 mg/kg x 1)
2. Praziquantel (20 mg/kg x 2)
3. Praziquantel (20 mg/kg x 3, 4 hours apart)
4. Placebo
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Katz 1979a BRA (Continued)
Outcomes 1. Cure rate
2. Adverse events
Notes Location: Brazil
Date of trial: not stated
Endemicity: N/A; military police
Communities studied: N/A
Brand: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Described as ’patients were randomly al-
located to treatment’, the authors refer
to WHO coordinated well-designed multi-
country trials of which this trial was part
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk Investigators, participants and assessors were
blind
Incomplete outcome data (attrition bias)
All outcomes
High risk Very small sample sizes (≤ 8 participants)
across arms, but losses reached over 50%
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Unclear risk Only male patients entered the trial
Katz 1979b BRA
Methods Length of follow-up: six and 12 months
Participants Number randomized: 61
Inclusion criteria: male patients aged 20 to 48 years from the military police of Minas
Gerais who were excreting > 100 EPG of S. mansoni (calculated from a minimum of two
stool samples).
Exclusion criteria: not stated
Diagnostic criteria: Kato-Katz thick smear (plus hatching test), three consecutive stool
(two slides from each stool plus three hatching tests on each stool); EPG expressed as
geometric mean
Interventions 1. Praziquantel (20 mg/kg x 3, 4 hours apart)
2. Praziquantel (50 mg/kg x 1)
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Katz 1979b BRA (Continued)
Outcomes 1. Cure rate
2. Adverse events
Notes Location: Brazil
Date of trial: not stated
Endemicity: N/A; military police
Communities studied: N/A
Brand: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Described as ’patients were randomly al-
located to treatment’. the authors refer
to WHO coordinated well-designed multi-
country trials of which this trial was part
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and assessors were blind
Incomplete outcome data (attrition bias)
All outcomes
High risk Losses > 20%
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Unclear risk Only male patients entered the trial
Katz 1981 BRA
Methods Length of follow-up: six months
Participants Number randomized: 138
Inclusion criteria: patients attending the hospital found to have S. mansoni infection
Exclusion criteria: not stated
Diagnostic criteria: Kato-Katz method (plus hatching test), three consecutive stools (two
slides fromeach stool plus three hatching tests on each stool ); EPGexpressed as geometric
mean
Interventions 1. Praziquantel (30 mg/kg x 1)
2. Praziquantel (40 mg/kg x 1)
3. Praziquantel (25 mg/kg x 2, 6 hours apart)
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Katz 1981 BRA (Continued)
Outcomes 1. Cure rate
2. Egg reduction rate
3. Adverse events
Notes Location: Brazil
Date of trial: not stated
Endemicity: N/A; hospital setting
Communities studied: N/A
Brand: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’Patients were randomly allocated to treatment’, no
further details given
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk Decribed as single-blind randomized trial, no further
details given
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses were low
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Unclear risk Only male patients entered the trial
Katz 1982 BRA
Methods Length of follow-up: six months
Participants Number randomized: 120
Inclusion criteria: children aged 8 to 14 years excreting between 90 and < 2,500 EPG,
weighing between 17 and 50 kg
Exclusion criteria: not stated
Diagnostic criteria: Kato-Katz thick smear, three consecutive stool samples (2 slides from
each stool); EGP expressed as geometric mean
Interventions 1. Oxamniquine (20 mg/kg x 1)
2. Praziquantel (65 mg/kg x 1)
Outcomes 1. Cure rate
2. Adverse events
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Katz 1982 BRA (Continued)
Notes Location: Brazil
Date of trial: not stated
Endemicity: N/A; hospital setting
Communities studied: outpatients (coming from two endemic communities)
Brand: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’This investigation was designed a double-blind
comparative trial between two parallel groups estab-
lished by random allocation of patients’, no further
details given
Allocation concealment (selection bias) Unclear risk Not described, but given that it was double-blind
trial, it is more likely allocation was concealed
Blinding (performance bias and detection
bias)
All outcomes
Low risk ’Double-blind trial’
Incomplete outcome data (attrition bias)
All outcomes
High risk Attrition rate high
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No other bias identified
Lambertucci 1982 BRA
Methods Table 15
Length of follow-up: 10 months
Participants Number randomized: 91
Inclusion criteria: children aged 6 to 14 years with chronic S. mansoni infection
Exclusion criteria: not stated
Diagnostic criteria: duplicate of two consecutive stools using Kato-Katz thick smear
Interventions 1. Oxamniquine (20 mg/kg x 1)
2. Placebo
Outcomes 1. Cure rate
2. Egg reduction rate
3. Adverse events
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Lambertucci 1982 BRA (Continued)
Notes Location: Brazil
Date of trial: November 1978 to January 1979
Endemicity: low (prevalence 8%)
Communities studied: outpatient clinic
Brand: not stated
Follow-up comprised 20quantitative parasitological stool examinations (two eachmonth
for 10 months)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as ’double-blind trial’, no further
details given
Allocation concealment (selection bias) Low risk Double-blind trial. The patients were iden-
tified on arrival at the hospital by a code
number in relation to oxamniquine or
placebo administration, to make it impos-
sible for the doctor in charge to know
which child took active drug and which the
placebo (double-blind). The code was bro-
ken 8months after the treatment of the last
patient’
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind trial
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition low (< 10%) and similar across
arms
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No other bias identified
Metwally 1995 EGY
Methods Length of follow-up: 1.5 and 2.5 months
Participants Number randomized: 366
Inclusion criteria: schoolchildren aged 8 to 16 years who were positive for S. mansoni
Exclusion criteria: children showing any signs of hepatosplenic disease, those who re-
ceived antischistosomal treatment within the previous six months
Diagnostic criteria: three consecutive stools (three slides per stool) using modified Kato-
Katz thick smear
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Metwally 1995 EGY (Continued)
Interventions 1. Praziquantel (40 mg/kg x 1): Biltricide
2. Praziquantel (40 mg/kg x 1): Distocide
Outcomes 1. Cure rate
2. Egg reduction rate
Notes Location: Egypt
Date of trial: not stated
Endemicity: high (prevalence not stated)
Communities studied: one
Brand: Biltricide and Distocide
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’Children were stratified into light, mod-
erate and heavy infection. Each stratified
group was randomly divided into four
groups’, no further details given
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk None described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not reported
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No other bias identified
Olds 1999 KEN
Methods Length of follow-up: five, 12 and 24 weeks, but the authors reported treatment effects
for 5 weeks only
Participants Number randomized: 367
Inclusion criteria: schoolchildren aged 6 to 19 years positive for S. mansoni
Exclusion criteria: failure to submit two stool specimens prior to the initial treatment,
known allergy to either drug, treatment with either drug within six months, lack of
consent, or possible pregnancy
Diagnostic criteria: two 50 mg stool slides each were prepared from 2 separate stool
samples for Kato-Katz thick smear
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Olds 1999 KEN (Continued)
Interventions 1. Albandazole (400 mg x 1) + praziquantel (40 mg/kg)
2. Praziquantel (40 mg/kg) + albendazole placebo
3. Albandazole (400 mg x 1) + praziquantel placebo
4. Both placebo
Outcomes 1. Cure rate
2. Adverse events
Notes Location: Kenya
Date of trial: not stated
Endemicity: high (prevalence > 80%)
Communities studied: one
Brand: not stated
Losses to follow-up were not statistically different in terms of treatment, infection status
or adverse events
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’Randomization lists were prepared by
WHO/TDR using a randomized block de-
sign with a block size of 80’
Allocation concealment (selection bias) Low risk Physically identical treatment and placebo
were manufactured and packaged on the
same equipment, and all bottles were iden-
tified only with a letter code. Randomiza-
tion code was not broken until after the 6-
month results were tabulated and submit-
ted to WHO
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind trial
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss to follow-up < 1% at 45 days
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No other bias identified
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Olliaro 2011 BRA
Methods Length of follow-up: three weeks
Participants Number randomized: 196
Inclusion criteria: participants aged 10 to 19 years with S. mansoni infection (≥ 100
EPG) using Kato-Katz technique, written informed consent, but under 18 years of age,
written informed consent fromparents/guardians and their verbal assent, able andwilling
to be examined on follow-up visits and provide stool samples
Exclusion criteria: pregnant or lactating, previous history of adverse reaction associated
with praziquantel, history of acute or chronic severe disease including hepato-splenic
schistosomiasis, recent use of praziquantel (within the last 30 days), with symptomatic
malaria, currently using other medication or in the past week
Interventions 1. Praziquantel (60 mg/kg x 1)
2. Praziquantel (40 mg/kg x 1)
Outcomes 1. Cure rate
2. Egg reduction rate
3. Reinfection rates
4. Hb level
5. Adverse events
Notes Location: Brazil
Date of trial: March 2006 to Dec 2007
Endemicity: prevalence 25%
Communities studied:
Brand: DistocideH by Shin-Poong, Korea
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’Randomization lists were prepared byWHO/TDR
using a randomized block design with a block size
of 4’
Allocation concealment (selection bias) Low risk ’Physically identical treatment and placebo were
manufactured and packaged on the same equip-
ment, and all bottles were identified only with a let-
ter code. Sealed and numbered envelopes were kept
in a locked cabinet by one responsible person; two
different people preparing treatment and evaluat-
ing patients; stool specimens read by a technician
blinded as to the treatment. Randomization code
was not broken until after the 6-month results were
tabulated and submitted to WHO’
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants, investigators and outcome assessors
were blind
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Olliaro 2011 BRA (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing or incomplete data considered as missing in
ITT and per protocol analyses
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No other bias identified
Olliaro 2011 MRT
Methods Length of follow-up: three weeks
Participants Number randomized:186
Inclusion criteria: participants aged 10 to 19 years with S. mansoni infection (≥ 100
EPG) using Kato-Katz technique, written informed consent, but under 18 years of age,
written informed consent fromparents/guardians and their verbal assent, able andwilling
to be examined on follow-up visits and provide stool samples
Exclusion criteria: pregnant or lactating, previous history of adverse reaction associated
with praziquantel, history of acute or chronic severe disease including hepato-splenic
schistosomiasis, recent use of praziquantel (within the last 30 days), with symptomatic
malaria, currently using other medication or in the past week
Interventions 1. Praziquantel (60 mg/kg x 1)
2. Praziquantel (40 mg/kg x 1)
Outcomes 1. Cure rate
2. Egg reduction rate
3. Reinfection rates
4. Hb level
5. Adverse events
Notes Location: Mauritania
Date of trial: August 2005 to December 2006
Endemicity: S. mansoni, prevalence 18.7%, S.haematobium prevalence 30.9%, Coinfec-
tion 7.3% and total prevalence 57%
Communities studied: not stated
Brand: DistocideH by Shin-Poong, Korea
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’Randomization lists were prepared byWHO/TDR
using a randomized block design with a block size
of 4’
Allocation concealment (selection bias) Low risk ’Physically identical treatment and placebo were
manufactured and packaged on the same equip-
ment, and all bottles were identified only with a let-
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Olliaro 2011 MRT (Continued)
ter code. Sealed and numbered envelopes were kept
in a locked cabinet by one responsible person; two
different people preparing treatment and evaluat-
ing patients; stool specimens read by a technician
blinded as to the treatment. Randomization code
was not broken until after the 6-month results were
tabulated and submitted to WHO’
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants, investigators and outcome assessors
were blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing or incomplete data considered as missing in
ITT and per protocol analyses
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No other bias identified
Olliaro 2011 TZA
Methods Length of follow-up: three weeks
Participants Number randomized: 271
Inclusion criteria: participants aged 10 to 19 years with S. mansoni infection (≥ 100
EPG) using Kato-Katz technique, written informed consent, but under 18 years of age,
written informed consent fromparents/guardians and their verbal assent, able andwilling
to be examined on follow-up visits and provide stool samples
Exclusion criteria: pregnant or lactating, previous history of adverse reaction associated
with praziquantel, history of acute or chronic severe disease including hepato-splenic
schistosomiasis, recent use of praziquantel (within the last 30 days), with symptomatic
malaria, currently using other medication or in the past week
Interventions 1. Praziquantel (60 mg/kg x 1)
2. Praziquantel (40 mg/kg x 1)
Outcomes 1. Cure rate
2. Egg reduction rate
3. Reinfection rates
4. Hb level
5. Adverse events
Notes Location: Tanzania
Date of trial: August 2005 to September 2006
Endemicity: high (prevalent not reported)
Communities studied: not stated
Brand: DistocideH by Shin-Poong, Korea
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Olliaro 2011 TZA (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’Randomization lists were prepared byWHO/TDR
using a randomized block design with a block size
of 4’
Allocation concealment (selection bias) Low risk ’Physically identical treatment and placebo were
manufactured and packaged on the same equip-
ment, and all bottles were identified only with a let-
ter code. Sealed and numbered envelopes were kept
in a locked cabinet by one responsible person; two
different people preparing treatment and evaluat-
ing patients; stool specimens read by a technician
blinded as to the treatment. Randomization code
was not broken until after the 6-month results were
tabulated and submitted to WHO’
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants, investigators and outcome assessors
were blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing or incomplete data considered as missing in
ITT and per protocol analyses
Selective reporting (reporting bias) Low risk No evidence of selective reporting.
Other bias Low risk No other bias identified.
Omer 1978 SDN
Methods Length of follow-up: one, two, three and six months
Participants Number randomized: 176
Inclusion criteria: individuals who were positive for S. mansoni and excreting > 250 EPG
Exclusion criteria: those with < 250 EPG, those with severe anaemia, ascites, or poor
general health, those who received antischistosomal drug within the last six months, and
pregnant women
Diagnostic criteria: three consecutive stools using modified Kato-Katz thick smear, Tees-
dale & Amin (Teesdale 1976)
Interventions 1. Oxamniquine (60 mg/kg): 15 mg/kg x 2 daily for 2 days
2. Oxamniquine (40 mg/kg): 20 mg/kg daily for 2 days
3. Oxamniquine (30 mg/kg): 15 mg/kg x 2 in one day
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Omer 1978 SDN (Continued)
Outcomes 1. Cure rate
2. Egg reduction rate
3. Adverse events
Notes Location: Sudan
Date of trial: 1975 to 1976
Endemicity: high (prevalence not stated)
Communities studied: outpatients
Brand: Biltricide
Only patients with moderate or heavy infections >250 EPG were included
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients randomly divided into blocks of
15 patients each’, no further details were
given
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and assessors were blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Losses were differential across arms: 14/73
(19%), 3/37 (8%) and 8/66 (12%) in the
60 mg/kg, 40 mg/kg and 30 mg/kg arms at
six months’ follow-up, respectively
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No other bias identified
Omer 1981 SDN
Methods Length of follow-up: 3 to 4 months, and six months
Participants Number randomized: 153
Inclusion criteria: individuals who were positive for S. mansoni and S. haematobium
(mixed infection)
Exclusion criteria: those < 8 years, with advanced disease, severe anaemia and poor general
health
Diagnostic criteria: three consecutive stools, usingmodifiedKato-Katz thick smear (Tees-
dale & Amin 1976)
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Omer 1981 SDN (Continued)
Interventions 1. Praziquantel (40 mg/kg x 1)
2. Praziquantel (20 mg/kg x 2)
3. Praziquantel (30 mg/kg x 1)
Outcomes 1. Cure rate
2. Adverse events
Notes Location: Sudan
Date of trial: 1978 to 1979
Endemicity: very high in the community (prevalence not given)
Communities studied: patients reporting to theHospital of Tropical Diseases, Khartoum
and those detected during a field survey
Brand: Biltricide
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The study was based on a protocol indicat-
ing stratification according to the degree of
infection which was determined by the ge-
ometric means of three stool sample exam-
inations. Each stratum was then randomly
divided into 3 blocks with 15 patients each
to receive one of three dosages’
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk ’Single blind trial, participants and asses-
sors were blind
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not reported
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No other bias identified
Queiroz 2010 BRA
Methods Follow-up: one, three and six months
Participants Inclusion criteria: inhabitants aged ≥ 13 years from Chonin (a district of Governador
Valadares) with a positive stool sample for S. mansoni infection
Criteria for exclusion from the study included pregnancy, cardiomyopathies and chronic
liver and renal diseases; however, no participants were excluded
Two parasitological stool examinations (2 slides per stool sample) by the quantitative
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Queiroz 2010 BRA (Continued)
Kato-Katz thick smear. Diagnostic criteria same pre-and post- treatment
Interventions 1. Praziquantel (80 mg/kg: 2 x 40 given 1 hour apart)
2. Praziquantel (50 mg/kg x 1)
Outcomes 1. Cure rate
2. Egg reduction rate
3. Adverse events
Notes Location: Brazil
Date of trial: 2002
Endemicity: moderate (prevalence 22.5%)
Communities studied: one
Brand: not stated
Patients with chronic schistosomiasis mansoni were recruited
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’Participants were randomly assigned into two
groups using small blocks to achieve balance
between them’
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk Single blind study, did not state who was
blinded. ’To keep the study masked, patients
who received 50 mg/kg received placebo 1 hour
after the first dose’
Incomplete outcome data (attrition bias)
All outcomes
Low risk Eighteen participants were lost to follow-up:
11/156 (7%) from the 80 mg/kg arm versus 7/
150 (5%) from the 50 mg/kg arm. Analysed by
ITT
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No other bias identified
Rezende 1985 BRA
Methods Length of follow-up: six months
Participants Number randomized: 539
Inclusion criteria: outpatients of all ages free from previous antischistosomal treatment;
whole populationwho received previous treatment of children and adults with S. mansoni
infection
Exclusion criteria: not stated
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Rezende 1985 BRA (Continued)
Diagnostic criteria: Kato-Katz thick smear (three smears from three consecutive stool
samples)
Interventions 1. Oxamniquine (16 mg/kg x 1)
2. Praziquantel (55 mg/kg x 1)
Outcomes 1. Failure rate
2. Egg reduction rate
3. Adverse events
Notes Location: Brazil
Date of trial: not stated
Endemicity: N/A; hospital setting
Communities studied: N/A
Brand: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomized double-blind parallel group clinical
trial
Allocation concealment (selection bias) Low risk Physically identical capsules were dispensed in indi-
vidually coded bottles
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind (investigators, participants and asses-
sors were blind)
Incomplete outcome data (attrition bias)
All outcomes
High risk Losses were high: 80/272 (29%) in oxamniquine 16
mg/kg arm versus 83/267 (31%) in the praziquantel
55 mg/kg arm
Selective reporting (reporting bias) Low risk No evidence of selecting reporting
Other bias Low risk No other bias identified
Rugemalila 1984 TZA
Methods Length of follow-up: one, two and six months
Participants Number randomized: 188 (125 included in the analysis)
Inclusion criteria: children aged 8 to 14 years attending primary school in Mwanza
district infected with S. mansoni
Exclusion criteria: not stated
Diagnostic criteria: single stool (duplicate slides) from formal-ether method
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Rugemalila 1984 TZA (Continued)
Interventions 1. Praziquantel (40 mg/kg x 1)
2. Oxamniquine (15 mg/kg x 1)
A third arm consisted of control (63 participants) who received no treatment and were
excluded
Outcomes 1. Adverse events
2. Resolution of symptoms
Notes Location: Tanzania
Date of trial: not stated
Endemicity: not stated
Communities studied: not stated
Brand: praziquantel (Biltricide, Bayer) and oxamniquine (Vancil, Pfizer)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Described as randomized single-blind com-
parative trial. ’The children found positive
for egg excretion were stratified for egg out-
put counts before being randomly allocated
by their serial numbers to one of the three
groups’
Allocation concealment (selection bias) Low risk ’The investigator giving treatment used
case serial numbers to check out the treat-
ment to be given. Case treatment groups
were not revealed to the examiners’
Blinding (performance bias and detection
bias)
All outcomes
Low risk Only the investigators were blind but this is
not likely to introduce bias into the results
Incomplete outcome data (attrition bias)
All outcomes
High risk Losses were high > 30% at three months
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No other bias identified
Shafei 1979 NGA
Methods Length of follow-up: one, two and three months
Participants Number randomized: 45
Inclusion criteria: individualswith S. mansoni infectiondetected in stool by theMcMaster
technique
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Shafei 1979 NGA (Continued)
Exclusion criteria: not stated
Diagnostic criteria: McMaster technique but did not state number of stool and slides
Interventions 1. Oxamniquine (15 mg/kg x 1)
2. Oxamniquine (15 mg/kg x 2 given one day)
Outcomes 1. Cure rate
2. Egg reduction rate
3. Adverse events
Notes Location: Nigeria
Date of trial: not stated
Endemicity: moderate (prevalence not stated)
Communities: one
Brand: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as ’randomized’, no further de-
tails given
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk None described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Sample size small, losses not reported
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No other bias identified
Stelma 1997 SEN
Methods Length of follow-up: 1.5 months
Participants Number randomized: 138
Inclusion criteria: patients aged > 5 years with S. mansoni infection
Exclusion criteria: pregnant women and children aged < 5 years
Diagnostic criteria: Kato-Katz thick smear (duplicate, two consecutive stools)
Interventions 1. Praziquantel (40 mg/kg x 1)
2. Oxamniquine (20 mg/kg x 1)
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Stelma 1997 SEN (Continued)
Outcomes 1. Cure rate
2. Egg reduction rate
Notes Location: Senegal
Date of trial: not stated
Endemicity: high (prevalence not stated)
Communities studied: one
Brand: praziquantel (Distocide, Shin Poong, Seoul Korea) and oxamniquine (Vansil,
Pfizer)
Cure rate extracted from graph
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Patients were randomly allocated to treatment, no
further details given
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses were recorded
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No other bias identified
Sukwa 1993 ZMB
Methods Length of follow-up: 12 months
Participants Number randomized: 377
Inclusion criteria: schoolchildren aged 7 to 19 years infected with S. mansoni
Exclusion criteria: not stated
Diagnostic criteria: single stool, duplicate slides of modified Kato-Katz thick smear
Interventions 1. Praziquantel (40 mg/kg x 2, given 6 months apart)
2. Praziquantel (40 mg/kg x 1, followed by placebo at 6 months)
Outcomes 1. Re-infection rate
2. Egg reduction rate
3. Resolution of pathology
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Sukwa 1993 ZMB (Continued)
Notes Location: Zambia
Date of trial: 1990 to 1991
Endemicity: high (prevalence not stated)
Communities studied: one
Brand: not stated
All children were treated with 40 mg/kg praziquantel at the start. Six months later the
children in group A were retreated with 40mg/kg praziquantel and group B with placebo
(multivitamin). They were all followed up for another six months (12 months total
follow-up)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Double-blind randomized trial, patients were ran-
domly allocated to treatment A and B, with a 1:1
allocation ratio and the school serving as the block’
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk Investigators, assessors and participants were blind
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not reported
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No other bias identified
Taddese 1988 ETH
Methods Length of follow-up: one, three and six months
Participants Number randomized: 200
Inclusion criteria: adolescents and adults aged 17 to 52 years infected with S. mansoni
and excreting at least 50 EPG (geometric mean)
Exclusion criteria: patients who had received antischistosomal treatment within the last
six months, lactating and pregnant women or having concurrent systemic diseases or
with a history of seizure disorders
Diagnostic criteria: Kato-Katz thick smear
Interventions 1. Praziquantel (40 mg/kg x 1)
2. Praziquantel (20 mg/kg x 2)
3. Oxamniquine (15 mg/kg x 1)
4. Oxamniquine (15 mg/kg x 2)
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Taddese 1988 ETH (Continued)
Outcomes 1. Cure rate
2. Egg reduction rate
3. Adverse events
Notes Location: Ethiopia
Date of trial: 1983
Endemicity: moderate (prevalence <30%)
Communities studied: one
Brand: praziquantel (Biltricide) and oxamniquine (Vansil)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Patients were randomly assigned to four
treatment groups, no further details given
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk None described
Incomplete outcome data (attrition bias)
All outcomes
High risk Losses were low in all arms (up to 10%),
but losses in one arm reached 18% by six
months
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No other bias identified
Taylor 1988 ZWE
Methods Length of follow-up: one, three and six months
Participants Number randomized: 373 (283 participants were included in the analysis)
Inclusion criteria: children aged 10 to 15 years who were all infected with both S. mansoni
and S. haematobium
Exclusion criteria: not stated
Diagnostic criteria: three consecutive stools using Kato-Katz thick smear (duplicate 41.
5 mg)
Interventions 1. Praziquantel (40 mg/kg x 1)
2. Praziquantel (30 mg/kg x 1)
3. Praziquantel (20 mg/kg x 1)
4. Praziquantel (10 mg/kg x 1)
A 5th arm consisting of 90 participants not treated was excluded from the analysis
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Taylor 1988 ZWE (Continued)
Outcomes 1. Failure rate
Notes Location: Zimbabwe
Date of trial: not stated
Endemicity: high (prevalence 76%)
Communities studied: one
Brand: not stated
Study was carried out during period of low transmission
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’Children were randomly assigned to treat-
ment groups’, no further details given
Allocation concealment (selection bias) Unclear risk Described as ’allocation concealed and ran-
domization code not broken until the end
of the trial’, methods not given
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and assessors were blind, only
the principal investigator was aware of the
groups to which participants had been as-
signed
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not reported
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No other bias identified
Teesdale 1984 MWI
Methods Length of follow-up: one and three months
Participants Number randomized: 119
Inclusion criteria: children aged 6 to 14 years with S. mansoni infection
Exclusion criteria: not stated
Diagnostic criteria: quantitative thick smear (Teesdale 25 mg) from 4 consecutive stools
Interventions 1. Oxamniquine (50 mg/kg): 25 mg/kg x 2
2. Oxamniquine (40 mg/kg x 1)
3. Oxamniquine (30 mg/kg x 1)
4. Praziquantel (40 mg/kg x 1)
A 5th arm involving 18 participants treated with oxamniquine (20 mg/kg x 1) was
excluded because it was not randomized as part of the trial
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Teesdale 1984 MWI (Continued)
Outcomes 1. Cure rate
2. Egg reduction rate
Notes Location: Malawi
Date of trial: not stated
Endemicity: high (prevalence not stated)
Communities studied: onemain village with another where only the 20 mg/kg was tested
Brand: Vansil
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’The positive subjects included in the study
were stratified by age and intensity of infec-
tion, and then randomized from each stra-
tum to four treatment groups’
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk None described
Incomplete outcome data (attrition bias)
All outcomes
High risk Losses at three months were high, reaching
77% in the oxamniquine 50 mg/kg arm
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No other bias identified
Tweyongyere 2009 UGA
Methods Length of follow-up: six weeks
Participants Number randomized: 387
Inclusion criteria: pregnant women found to have S. mansoni infected detected during a
population survey
Exclusion criteria: those < 8 years, with advanced disease, severe anaemia and poor general
health
Diagnostic criteria: single stool sample of duplicate Kato-Katz thick smear for both pre-
and post-treatment
Interventions 1. Praziquantel (40 mg/kg x 1)
2. Placebo
Outcomes 1. Cure rate
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Tweyongyere 2009 UGA (Continued)
Notes Location: Uganda
Date of trial: 2003 to 2005
Endemicity: high (prevalence not stated)
Communities studied: not stated
Brand: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Prepared by statistician with Stata 7 in blocks of 100
Allocation concealment (selection bias) Low risk Opaque, sealed envelopes
Blinding (performance bias and detection
bias)
All outcomes
Low risk Investigators, assessors and participants were blind
Incomplete outcome data (attrition bias)
All outcomes
High risk Losses were high in both the praziquantel 59/186
(32%) and placebo 88/201 (44%)
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No other bias reported
Zwingenberger 1987 BRA
Methods Length of follow-up: three, six and 12 months
Participants Number randomized: 91
Inclusion criteria: individuals aged 10 to 62 years with S. mansoni diagnosed in a para-
sitological survey
Exclusion criteria: not stated
Diagnostic criteria: Kato-Katz thick smear (single stool)
Interventions 1. Praziquantel (20 mg/kg x 2)
2. Oxamniquine (15 mg/kg x 1)
3. Oxamniquine (7.5 mg/kg) plus praziquantel (20 mg/kg)
Outcomes 1. Cure rate
2. Egg reduction rate
Notes Location: Brazil
Date of trial: not stated
Endemicity: high (prevalence not stated)
Communities studied: one
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Zwingenberger 1987 BRA (Continued)
Brand: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Patients were randomly allocated to one of
three groups, no further details given
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk None described
Incomplete outcome data (attrition bias)
All outcomes
High risk Losses were high reaching > 40% in one
arm
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No other bias identified
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abu-Elyazeed 1997 Not randomized, selective treatment
Adam 2008 Praziquantel versus anti-malaria treatment
Almeida 2012 Randomized controlled trial, but not outcome of interest
Assis 1998 Reported anthropometry, which is not part of this review
Boisier 1998 Not randomized, selective treatment
Coura 1980 Not randomized, selective treatment
De Clercq 2000b Not randomized, selective treatment
Doehring 1992 Randomized, but did not report results of each arm separately. The results of the different arms were rather
combined and presented as one
Eigege 2008 Not randomized
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(Continued)
el Guiniady 1994 Not randomized
el-Hawey 1991 Not randomized
Friis 1997 Effect of zinc supplementation on growth and body weight
Friis 2003 Mineral supplementation
Gryseels 1987 Not randomized, selective treatment
Homeida 1988 Not randomized
Kabatereine 2003 Not randomized, selective treatment
Katz 1973 Not randomized
Mohamed 2009 Praziquantel versus anti-malaria treatment
Navaratnam 2012 The study recruited both children with and without the infection
Obonyo 2010 Praziquantel versus anti-malaria treatment
Odongo-Aginya 1996 Not randomized, selective treatment
Olsen 2000 No drug treatment, mineral supplementation
Olsen 2003 No drug treatment, mineral supplementation
Pitchford 1978 No comparison group
Polderman 1988 Not randomized, selective treatment
Utzinger 2000a Artemether given to non-infected people for the prevention of S. mansoni infection
Utzinger 2000b Not randomized, selective treatment
van Lieshout 1994 Not randomized, selective treatment
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D A T A A N D A N A L Y S E S
Comparison 1. Praziquantel versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Parasitological failure at one
month
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 40 mg/kg single dose 2 414 Risk Ratio (M-H, Random, 95% CI) 3.13 [1.03, 9.53]
2 Parasitological failure at six
months
2 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 20 mg/kg single dose 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 40 mg/kg in two divided
doses on the same day
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 60 mg/kg in 3 divided
doses 3 hours apart
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.4 60 mg/kg daily for 3 days 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Parasitological failure at 12
months
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 20 mg/kg single dose 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 40 mg/kg in two divided
doses on the same day
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.3 60 mg/kg in 3 divided
doses 3 hours apart
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 2. Praziquantel (lower dose) versus praziquantel 40 mg/kg
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Parasitological failure at one
month
3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Praziquantel 20 mg/kg
versus praziquantel 40 mg/kg
2 341 Risk Ratio (M-H, Fixed, 95% CI) 2.23 [1.64, 3.02]
1.2 Praziquantel 30 mg/kg
versus praziquantel 40 mg/kg
3 521 Risk Ratio (M-H, Fixed, 95% CI) 1.52 [1.15, 2.01]
2 Parasitological failure at three
months
3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Praziquantel 20 mg/kg
versus praziquantel 40 mg/kg
2 325 Risk Ratio (M-H, Fixed, 95% CI) 2.15 [1.66, 2.79]
2.2 Praziquantel 30 mg/kg
versus praziquantel 40 mg/kg
3 508 Risk Ratio (M-H, Fixed, 95% CI) 1.40 [1.10, 1.77]
3 Parasitological failure at six to 12
months
6 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Praziquantel 20 mg/kg
versus praziquantel 40 mg/kg
3 350 Risk Ratio (M-H, Random, 95% CI) 2.54 [1.35, 4.76]
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3.2 Praziquantel 30 mg/kg
versus praziquantel 40 mg/kg
5 651 Risk Ratio (M-H, Random, 95% CI) 1.48 [1.19, 1.85]
4 Percent egg reduction Other data No numeric data
Comparison 3. Praziquantel lower dose (20 and 30 mg/kg) versus praziquantel 40 mg/kg
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Resolution of abdominal pain:
20 mg/kg versus 40 mg/kg
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 One month 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Three months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 Six months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.4 12 months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.5 24 months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Resolution of abdominal pain:
30 mg/kg versus 40 mg/kg
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 One month 2 318 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.55, 1.10]
2.2 Three months 2 318 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.53, 1.11]
2.3 Six months 2 318 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.52, 1.08]
2.4 12 months 2 318 Risk Ratio (M-H, Fixed, 95% CI) 0.59 [0.35, 1.01]
2.5 24 months 2 318 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.55, 1.25]
3 Resolution of diarrhoea: 20 mg/
kg versus 40 mg/kg
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 One month 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Three months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.3 Six months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.4 12 months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.5 24 months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Resolution of diarrhoea: 30 mg/
kg versus 40 mg/kg
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 One month 2 48 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.70, 1.03]
4.2 Three months 2 48 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.82, 1.25]
4.3 Six months 2 48 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.76, 1.22]
4.4 12 months 2 48 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.77, 1.37]
4.5 24 months 2 48 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.69, 1.23]
5 Resolution of blood in stool: 20
mg/kg versus 40 mg/kg
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
5.1 One month 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 Three months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.3 Six months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.4 12 months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.5 24 months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Resolution of blood in stool: 30
mg/kg versus 40 mg/kg
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 One month 2 80 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.89, 1.11]
6.2 Three months 2 80 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.91, 1.13]
6.3 Six months 2 80 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.87, 1.07]
6.4 12 months 2 82 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.79, 1.22]
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6.5 24 months 2 82 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [0.78, 1.40]
7 Resolution of hepatomegaly: 20
mg/kg versus 40 mg/kg
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
7.1 One month 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.2 Three months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.3 Six months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.4 12 months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.5 24 months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Resolution of hepatomegaly: 30
mg/kg versus 40 mg/kg
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 One month 2 109 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.83, 1.35]
8.2 Three months 2 109 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.80, 1.27]
8.3 Six months 2 109 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.79, 1.29]
8.4 12 months 2 109 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.73, 1.16]
8.5 24 months 2 109 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.69, 1.14]
9 Resolution of splenomegaly: 20
mg/kg versus 40 mg/kg
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
9.1 One month 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.2 Three months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.3 Six months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.4 12 months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.5 24 months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10 Resolution of splenomegaly: 30
mg/kg versus 40 mg/kg
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
10.1 One month 2 122 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.65, 1.15]
10.2 Three months 2 122 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.66, 1.25]
10.3 Six months 2 122 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.70, 1.36]
10.4 12 months 2 122 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [0.76, 1.46]
10.5 24 months 2 122 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.72, 1.23]
Comparison 4. Praziquantel (higher dose) versus praziquantel 40 mg/kg
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Parasitological failure at one
month
4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Praziquantel 60 mg/kg
versus praziquantel 40 mg/kg
4 783 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.73, 1.29]
2 Parasitological failure at six
months
2 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 Praziquantel 50 mg/kg
versus praziquantel 40 mg/kg
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Praziquantel 60 mg/kg
versus praziquantel 40 mg/kg
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Parasitological failure at six to 12
months
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 Praziquantel 60 mg/kg
versus praziquantel 40 mg/kg
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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4 Percent egg reduction at one
month
Other data No numeric data
Comparison 5. Praziquantel 40 mg/kg divided dose versus praziquantel 40 mg/kg single dose
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Parasitological failure at one
month
2 525 Risk Ratio (M-H, Random, 95% CI) 0.47 [0.13, 1.69]
2 Parasitological failure at three
months
2 516 Risk Ratio (M-H, Random, 95% CI) 0.31 [0.18, 0.53]
3 Parasitological failure at six
months
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4 Percent egg reduction at one
month
Other data No numeric data
Comparison 6. Praziquantel alternative dosing (Brazil)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Parasitological failure at six
months
3 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Praziquantel 30 mg/kg
x 2 daily for 2 days versus
praziquantel 30 mg/kg x 2 in
one day
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Praziquantel 30 mg/kg
x 2 daily for 3 days versus
praziquantel 30 mg/kg x 2 in
one day
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 Praziquantel 30 mg/kg x 1
daily for 6 days versus 30 mg/
kg x 2 in one day
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.4 Praziquantel 20 mg/
kg x 3, 4 hours apart versus
praziquantel 50 mg/kg single
dose
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.5 Praziquantel 40 mg/
kg x 2, 1 hour apart versus
praziquantel 50 mg/kg single
dose
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Percent egg reduction at six
months
Other data No numeric data
3 Percent egg reduction at six
months
Other data No numeric data
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4 Percent egg reduction at six
months
Other data No numeric data
Comparison 7. Oxamniquine versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Parasitological failure at three to
four months
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 30 mg/kg 2 82 Risk Ratio (M-H, Fixed, 95% CI) 4.34 [2.47, 7.65]
1.2 40 mg/kg 2 82 Risk Ratio (M-H, Fixed, 95% CI) 8.74 [3.74, 20.43]
1.3 60 mg/kg 2 89 Risk Ratio (M-H, Fixed, 95% CI) 19.38 [5.79, 64.79]
2 Parasitological failure at six to 10
months
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 20 mg/kg 2 146 Risk Ratio (M-H, Fixed, 95% CI) 3.68 [2.53, 5.36]
3 Percent egg reduction at three to
four months
Other data No numeric data
3.1 Oxamniquine (40 mg/kg)
versus placebo
Other data No numeric data
3.2 Oxamniquine (20 to 30
mg/kg) versus placebo
Other data No numeric data
3.3 Oxamniquine (60 mg/kg)
versus placebo
Other data No numeric data
Comparison 8. Oxamniquine (lower dose) versus oxamniquine 40 mg/kg
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Parasitological failure at one
month
5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Oxamniquine 20 mg/kg
versus oxamniquine 40 mg/kg
2 190 Risk Ratio (M-H, Fixed, 95% CI) 3.78 [2.05, 6.99]
1.2 Oxamniquine 30 mg/kg
versus oxamniquine 40 mg/kg
4 268 Risk Ratio (M-H, Fixed, 95% CI) 1.78 [1.15, 2.75]
2 Parasitological failure at three to
four months
8 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Oxamniquine 20 mg/kg
versus oxamniquine 40 mg/kg
3 209 Risk Ratio (M-H, Fixed, 95% CI) 2.28 [1.40, 3.71]
2.2 Oxamniquine 30 mg/kg
versus oxamniquine 40 mg/kg
7 373 Risk Ratio (M-H, Fixed, 95% CI) 1.64 [1.10, 2.43]
3 Parasitological failure at six
months
4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Oxamniquine 20 mg/kg
versus oxamniquine 40 mg/kg
2 163 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.48, 1.46]
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3.2 Oxamniquine 30 mg/kg
versus oxamniquine 40 mg/kg
3 214 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.71, 1.69]
4 Parasitological failure at 12
months
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Oxamniquine 20 mg/kg
versus oxamniquine 40 mg/kg
2 144 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.32, 2.36]
4.2 Oxamniquine 30 mg/kg
versus oxamniquine 40 mg/kg
1 77 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.67, 1.31]
5 Percent egg reduction Other data No numeric data
5.1 One month Other data No numeric data
5.2 Three to four months Other data No numeric data
5.3 Six months Other data No numeric data
Comparison 9. Oxamniquine lower dose (20 and 30 mg/kg) versus oxamniquine 40 mg/kg
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Resolution of abdominal pain:
20 mg/kg versus 40 mg/kg
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 One month 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Three months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 Six months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.4 12 months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.5 24 months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Resolution of abdominal pain:
30 mg/kg versus 40 mg/kg
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 One month 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Three months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 Six months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.4 12 months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.5 24 months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Resolution of diarrhoea: 20 mg/
kg versus 40 mg/kg
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 One month 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Three months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.3 Six months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.4 12 months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.5 24 months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Resolution of diarrhoea: 30 mg/
kg versus 40 mg/kg
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4.1 One month 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 Three months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.3 Six months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.4 12 months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.5 24 months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Resolution of blood in stool: 20
mg/kg versus 40 mg/kg
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
5.1 One month 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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5.2 Three months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.3 Six months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.4 12 months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.5 24 months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Resolution of blood in stool: 30
mg/kg versus 40 mg/kg
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
6.1 One month 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.2 Three months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.3 Six months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.4 12 months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.5 24 months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Resolution of hepatomegaly: 20
mg/kg versus 40 mg/kg
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
7.1 One month 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.2 Three months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.3 Six months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.4 12 months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.5 24 months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Resolution of hepatomegaly: 30
mg/kg versus 40 mg/kg
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
8.1 One month 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.2 Three months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.3 Six months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.4 12 months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.5 24 months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Resolution of splenomegaly: 20
mg/kg versus 40 mg/kg
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
9.1 One month 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.2 Three months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.3 Six months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.4 12 months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.5 24 months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10 Resolution of splenomegaly: 30
mg/kg versus 40 mg/kg
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
10.1 One month 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.2 Three months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.3 Six months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.4 12 months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.5 24 months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 10. Oxamniquine (higher dose) versus oxamniquine 40 mg/kg
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Parasitological failure at one
month
5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
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1.1 Oxamniquine (50 mg/kg)
versus oxamniquine (40 mg/
kg)
1 32 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.21, 3.73]
1.2 Oxamniquine (60 mg/kg)
versus oxamniquine (40 mg/
kg)
4 317 Risk Ratio (M-H, Random, 95% CI) 0.45 [0.09, 2.11]
2 Parasitological failure at three to
four months
6 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Oxamniquine (50 mg/kg)
versus oxamniquine (40 mg/
kg)
1 16 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.25, 4.86]
2.2 Oxamniquine (60 mg/kg)
versus oxamniquine (40 mg/
kg)
5 381 Risk Ratio (M-H, Random, 95% CI) 0.40 [0.12, 1.38]
3 Parasitological failure at six
months
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Oxamniquine (60 mg/kg)
versus oxamniquine (40 mg/
kg)
2 177 Risk Ratio (M-H, Random, 95% CI) 0.61 [0.12, 3.12]
4 Percent egg reduction Other data No numeric data
4.1 One month Other data No numeric data
4.2 Three to four months Other data No numeric data
4.3 Six months Other data No numeric data
Comparison 11. Oxamniquine (lower dose) 15 to 20 mg/kg versus oxamniquine 30 mg/kg
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Parasitological failure 4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 One month 3 230 Risk Ratio (M-H, Fixed, 95% CI) 1.77 [1.14, 2.74]
1.2 Three to four months 4 249 Risk Ratio (M-H, Fixed, 95% CI) 2.16 [1.40, 3.32]
1.3 Six months 2 179 Risk Ratio (M-H, Fixed, 95% CI) 1.23 [0.86, 1.75]
1.4 6 to 12 months 1 95 Risk Ratio (M-H, Fixed, 95% CI) 1.74 [1.02, 2.96]
Comparison 12. Oxamniquine (higher dose) versus oxamniquine 30 mg/kg
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Parasitological failure at one
month
3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Oxamniquine 50 mg/kg
versus oxamniquine 30 mg/kg
1 36 Risk Ratio (M-H, Fixed, 95% CI) 0.48 [0.15, 1.56]
1.2 Oxamniquine 60 mg/kg
versus oxamniquine 30 mg/kg
2 175 Risk Ratio (M-H, Fixed, 95% CI) 0.04 [0.01, 0.26]
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2 Parasitological failure at three to
four months
6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Oxamniquine 50 mg/kg
versus oxamniquine 30 mg/kg
2 53 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.44, 1.53]
2.2 Oxamniquine 60 mg/kg
versus oxamniquine 30 mg/kg
4 265 Risk Ratio (M-H, Fixed, 95% CI) 0.17 [0.07, 0.39]
3 Parasitological failure at six
months
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Oxamniquine (60 mg/kg)
versus oxamniquine (30 mg/
kg)
2 157 Risk Ratio (M-H, Fixed, 95% CI) 0.17 [0.06, 0.50]
Comparison 13. Oxamniquine versus praziquantel
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Parasitological failure at one
month
4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Oxamniquine 10 to 20
mg/kg versus praziquantel 40
mg/kg
2 232 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.08, 14.47]
1.2 Oxamniquine 30 mg/kg
versus praziquantel 40 mg/kg
2 136 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.35, 1.45]
1.3 Oxamniquine 40 mg/kg
versus praziquantel 40 mg/kg
1 33 Risk Ratio (M-H, Random, 95% CI) 0.4 [0.13, 1.22]
1.4 Oxamniquine 50 to 60
mg/kg versus praziquantel 40
mg/kg
2 122 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.16, 4.84]
2 Parasitological failure at three
months
4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Oxamniquine (10 to 20
mg/kg) versus praziquantel 40
mg/kg
2 135 Risk Ratio (M-H, Random, 95% CI) 3.42 [1.10, 10.61]
2.2 Oxamniquine (25 to 30
mg/kg) versus praziquantel 40
mg/kg
3 319 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.40, 2.12]
2.3 Oxamniquine 40 mg/kg
versus praziquantel 40 mg/kg
1 18 Risk Ratio (M-H, Random, 95% CI) 0.4 [0.14, 1.12]
2.4 Oxamniquine (50 to 60
mg/kg) versus praziquantel 40
mg/kg
1 14 Risk Ratio (M-H, Random, 95% CI) 0.44 [0.13, 1.48]
3 Parasitological failure at six
months
9 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Oxamniquine (10 to 20
mg/kg) versus praziquantel 40
mg/kg
3 197 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.70, 1.74]
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3.2 Oxamniquine (25 to 30
mg/kg) versus praziquantel 40
mg/kg
2 295 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.22, 4.49]
3.3 Oxamniquine (50 to 60
mg/kg) versus praziquantel 40
mg/kg
1 79 Risk Ratio (M-H, Random, 95% CI) 2.19 [1.11, 4.30]
3.4 Oxamniquine (15 to 20
mg/kg) versus praziquantel 40
mg/kg
4 596 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.83, 1.51]
4 Parasitological failure at 12
months
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4.1 Oxamniquine (10 to 20
mg/kg) versus praziquantel 40
mg/kg
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Percent egg reduction Other data No numeric data
5.1 One month Other data No numeric data
5.2 Three months Other data No numeric data
5.3 Six months Other data No numeric data
5.4 12 months Other data No numeric data
Comparison 14. Myrrh (Mirazid) 300 mg once daily for three days versus praziquantel 40 mg/kg
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Parasitological failure at three to
six weeks
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2 Percent egg reduction three to
six weeks
Other data No numeric data
Comparison 15. Praziquantel (40 mg/kg) plus artesunate (12 mg/kg total dose) versus praziquantel (40 mg/kg)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Parasitological failure at one
month
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Parasitological failure at three
months
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3 Parasitological failure at six
months
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4 Percent egg reduction Other data No numeric data
4.1 One month Other data No numeric data
4.2 Three months Other data No numeric data
4.3 Six months Other data No numeric data
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Comparison 16. Praziquantel (20 mg/kg) plus oxamniquine (7.5 mg/kg) versus praziquantel (40 mg/kg)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Parasitological failure at three
months
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Parasitological failure at six
months
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3 Parasitological failure at 12
months
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4 Percent egg reduction Other data No numeric data
4.1 Three months Other data No numeric data
4.2 Six months Other data No numeric data
4.3 12 months Other data No numeric data
Comparison 17. Praziquantel (8 mg/kg) plus oxamniquine (4 mg/kg) versus praziquantel (20 mg/kg) plus
oxamniquine (10 mg/kg)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Parasitological failure at one
month
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Parasitological failure at three
months
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3 Parasitological failure at six
months
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4 Percent egg reduction Other data No numeric data
4.1 One month Other data No numeric data
4.2 Three months Other data No numeric data
4.3 Six months Other data No numeric data
Comparison 18. Praziquantel (15 mg/kg) plus oxamniquine (7.5 mg/kg) versus praziquantel (20 mg/kg) plus
oxamniquine (10 mg/kg)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Parasitological failure at one
month
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Parasitological failure at three
months
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3 Parasitological failure at six
months
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4 Percent egg reduction Other data No numeric data
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4.1 One month Other data No numeric data
4.2 Three months Other data No numeric data
4.3 Six months Other data No numeric data
A D D I T I O N A L T A B L E S
Table 1. Detailed search strategies
Search set CIDG SRˆ CENTRAL MEDLINEˆˆ EMBASEˆˆ LILACSˆˆ
1 Schisto* mansoni SCHISTOSOMA
MANSONI
SCHISTOSOMA
MANSONI
SCHISTOSOMA
MANSONI
Schisto$ mansoni
2 Esquistossomose SCHISTOSOMIA-
SIS MANSONI
SCHISTOSOMIA-
SIS MANSONI
SCHISTOSOMIA-
SIS MANSONI
Esquistossomose
3 1 or 2 Intestinal schistosom*
ti, ab
Intestinal schistosom*
ti, ab
Intestinal
schistosom$ ti, ab
1 or 2
4 Bilharzia* Bilharzia* Bilharzia$
5 Esquistossomose ti,
ab
Esquistossomose ti,
ab
Esquistossomose ti,
ab
6 Schistosomicide* Schistosomicide* Schistosomicide$
7 1 or 2 or 3 or 4 or 5 or
6
1 or 2 or 3 or 4 or 5 or
6
1 or 2 or 3 or 4 or 5 or
6
8 Limit 7 to humans Limit 7 to humans
ˆCochrane Infectious
Diseases Group Spe-
cialized Register
ˆˆSearch terms used in
combination with the
search strategy for re-
trieving tri-
als developed by The
Cochrane Collabora-
tion (Higgins 2011)
; Upper case: MeSH
orEMTREEheading;
Lower case: free text
term
Table 2. Adverse events: Praziquantel versus placebo
Trial No. of participants Praziquantel dose Remarks
Jaoko 1996 KEN 436 40 mg/kg single dose Adverse events described as minor and
transient.
Dizziness: Praziquantel 36% versus 6%
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Table 2. Adverse events: Praziquantel versus placebo (Continued)
control
Abdominal pain 35% versus 14 % con-
trol
Katz 1979a BRA 55 20 mg/kg single dose
40 mg/kg: 20 mg/kg twice in one day
60 mg/kg: 20 mg/kg three times in one
day
Adverse events were minor, did not dif-
fer between intervention and placebo
groups, but were not reported separately
for the different dose schedules
Katz 1979b BRA 61 50 mg/kg single dose
60 mg/kg: 20 mg/kg three times in one
day
Adverse events were minor, did not dif-
fer between the two intervention groups,
but were not reported separately for the
two dosing schedules
Olds 1999 KEN 174 40 mg/kg single dose Abdominal pain: Praziquantel 80% ver-
sus 50% control
Diarrhoea: Praziquantel 54% versus
25% control
Tweyongyere 2009 UGA 387 40 mg/kg single dose Adverse eventswereminor and transient.
The authors pooled adverse events to-
gether over the intervention and placebo
groups. Event rates were not reported
Branchini 1982 BRA 70 41.2 to 51.6 mg/kg single dose No serious adverse events. Dizziness:
Praziquantel 46.9% (control group not
reported)
Abdominal pain: Praziquantel 24.5%
versus 17.6% control
Ferrari 2003 BRA 72 180 mg/kg: 60 mg/kg once daily for
three days
No serious adverse events. Events were
mostly headache, dizziness, drowsiness
and abdominal pain. Patients from the
placebo group also reported having ab-
dominal pain and drowsiness
Table 3. Adverse events: praziquantel (lower dose) versus 40 mg/kg
Trial No. of participants Comparison Remarks
Katz 1979a BRA 28 20 mg/kg single dose
40 mg/kg: 20 mg/kg twice in one day
No serious adverse events. Minor adverse
events, did not differ between intervention
and control groups
Katz 1981 BRA 138 30 mg/kg single dose
40 mg/kg single dose
No serious adverse events. Minor adverse
events (lower dose first):
Abdominal pain: 42.6% versus 44.4%
Giddiness: 14.9% versus 26.7%
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Table 3. Adverse events: praziquantel (lower dose) versus 40 mg/kg (Continued)
Omer 1981 SDN 153 30 mg/kg single dose
40 mg/kg single dose
No serious adverse events. Diarrhoea, vom-
iting, nausea and abdominal pain were com-
monly reported but these were transient
Table 4. Adverse events: praziquantel (higher dose) versus 40 mg/kg
Trial No. of participants Comparison Remarks
Olliaro 2011 BRA 196 60 mg/kg single dose
40 mg/kg single dose
No serious adverse event. Minor adverse
events (highest dose first):
Abdominal pain: 48 versus 47.9%
Nausea: 20.4% versus 18.4%
Dizziness: 20.4% versus 11.2%
Headache: 14.3% versus 12.2%
Vomiting: 11.2% versus 5.19%
Diarrhoea: 8.2% versus 4.1%
Rarely sleepiness was also reported.
Olliaro 2011 MRT 186 60 mg/kg single dose
40 mg/kg single dose
One incidence of serious eventwas recorded
in the higher dose (60 mg/kg). The rest of
the events were minor. Transient dizziness,
abdominal pain, diarrhoea, vomiting and
headachewere commonly reported (highest
dose first):
Dizziness: 77.8% versus 9.7%
Abdominal pain:79.6% versus 71.0%
Diarrhoea: 41.9% versus 49.5%
Vomiting: 10.7% versus 32.3%
Headache: 9.7% versus 14.0%
Olliaro 2011 TZA 271 60 mg/kg single dose
40 mg/kg single dose
Minor adverse events (highest dose first):
Abdominal pain: 88.9% versus 83.8%
Diarrhoea: 47.4% versus 49.3%
Nausea: 26.7% versus 30.9%
Headache: 14.1% versus 9.6%
Vomiting: 11.1% versus 16.9%
Dizziness: 6.7% versus 9.6%
Fever: 0% versus 1.5%.
Table 5. Adverse events: praziquantel (40 mg/kg in a divided dose) versus praziquantel (40 mg/kg) single dose
Trial No. of participants Comparison Remarks
Kardaman 1983 SDN 350 40 mg/kg: 20 mg/kg twice in a day
40 mg/kg single dose
No serious adverse events. Events were
transient (divided dose first): Abdominal
pain: 13.5% versus 24.6%
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Table 5. Adverse events: praziquantel (40 mg/kg in a divided dose) versus praziquantel (40 mg/kg) single dose (Continued)
Vomiting: 7.6% versus 4%
Diarrhoea: 7.6% versus 12.8%
Omer 1981 SDN 306 40 mg/kg: 20 mg/kg twice in a day
40 mg/kg single dose
No serious adverse events.
Adverse events were transient and re-
quired no additional intervention
Table 6. Adverse events: praziquantel alternative dosing (Brazil)
Trial No. of participants Comparison Remarks
da Cunha 1987 BRA 79 180 mg/kg: 30 mg/kg twice daily for three
days
180 mg/kg: 30 mg/kg daily for six days
120 mg/kg: 30 mg/kg twice daily for two
days
60 mg/kg: 30 mg/kg twice in one day
No serious adverse events.
Minor and transient events (highest dose
first):
Dizziness: 65%, 15%, 45% versus 15%
Nausea: 55%, 15, 20% versus 20%
Table 7. Adverse events: oxamniquine versus placebo
Trial No. of participants Oxamniquine dose Remarks
Ayele 1984 ETH 65 60 mg/kg: 15 mg/kg twice daily for two
days
40 mg/kg: 10 mg/kg twice daily for two
days
30 mg/kg: 15 mg/kg twice in one day
Adverse events were minor and transient.
Dizziness: Oxamniquine (15 mg/kg BD
for 2 days) 50% versus 38.9% (10 mg/
kg BD for two days) versus 30% control
Ayele 1986 ETH 128 60 mg/kg: 15 mg/kg twice daily for two
days
40 mg/kg: 20 mg/kg twice in one day
30 mg/kg: 15 mg/kg twice in one day
All the doses were well tolerated and
accepted. Dizziness was the most fre-
quently reported complaint, but this was
mild and transient
Lambertucci 1982 BRA 91 20 mg/kg single dose Adverse events were minor and transient.
Dizziness:Oxamniquine 14.6%versus 2.
8% control
Nausea: Oxamniquine 14.6% versus 5.
6% control.
Branchini 1982 BRA 71 14 mg/kg single dose Adverse events were few and minor.
Dizziness: Oxamniquine 44.2% (control
not reported)
Abdominal pain: Oxamniquine 11.5%
versus 17.6% control.
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Table 7. Adverse events: oxamniquine versus placebo (Continued)
Ferrari 2003 BRA 70 20 mg/kg: 10 mg/kg twice in one day No serious adverse events.
Adverse events were mild, mostly
headache, dizziness, drowsiness and ab-
dominal pain. Patients from the placebo
group also had abdominal pain and
drowsiness
Table 8. Adverse events: oxamniquine (lower dose) versus 40 mg/kg
Trial No. of participants Comparison Remarks
Ayele 1984 ETH 55 30 mg/kg: 15 mg/kg twice in one day. No serious adverse events were reported.
Transient dizziness and nausea were com-
monly reported (lower dose first):
Dizziness: 38.9% versus 42%
Nausea: 22.2% versus 26.3%
A few mild headaches and abdominal
pain were also reported.
Ayele 1986 ETH 96 30 mg/kg:15 mg/kg twice in one day. All doses were well tolerated and no se-
rious event was recorded. Dizziness was
more commonly reported, but this was
transient
de Clarke 1976b ZWE 26 20 mg/kg: 5 x 2 mg/kg daily for two days
30 mg/kg: 7.5 x 2 mg/kg daily for two
days.
No serious adverse events were recorded.
Transient dizziness was more commonly
reported and very rarely headache, nau-
sea, and vomiting. Adverse events did not
differ between dose
Gupta 1984 ZMB 60 30 mg/kg:15 mg/kg twice in one day
40 mg/kg: 10 mg/kg twice daily for two
days
No serious events were reported. Adverse
events were mainly dizziness and nausea,
but were minor and transient (lower dose
first):
Dizziness: 20% versus 25%
Nausea: 15% versus 30%
A few events of vomiting, headache and
abdominal pain were also reported
Omer 1978 SDN 176 30 mg/kg: 15 mg/kg twice in one day
40 mg/kg: 20 mg/kg daily for 2 days
No serious adverse events were recorded.
Asthenia (weakness) was reported among
a few receiving 40mg/kg, but this did not
require additional intervention.Transient
dizziness was more commonly reported
(lower dose first)
Dizziness: 3% versus 8%
Minor abdominal pain, headache and
vomiting also reported.
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Table 8. Adverse events: oxamniquine (lower dose) versus 40 mg/kg (Continued)
Teesdale 1984 MWI 95 20 mg/kg single dose
30 mg/kg single dose
Noserious adverse events were recorded.
Transient dizziness, nausea and vomiting
were most commonly reported
Table 9. Adverse events: oxamniquine (higher dose) versus 40 mg/kg
Trial No. of participants Comparison Remarks
Ayele 1984 ETH 55 60 mg/kg: 15 mg/kg twice daily for two
days
40 mg/kg: 10 mg/kg twice daily for two
days
No serious adverse event was recorded.
Dizziness and nausea were commonly re-
ported but these were transient (higher
dose first):
Dizziness: 50% versus 42%
Nausea: 11% versus 26.3%
A few mild headaches and abdominal pain
were also reported.
Ayele 1986 ETH 96 60 mg/kg: 15 mg/kg twice daily for 2 days
40 mg/kg: 20 mg/kg twice in one day
No serious adverse events were recorded.
Dizziness was more commonly reported,
but this was transient and did not differ
between dose
Gupta 1984 ZMB 60 60 mg/kg: 15 mg/kg twice daily for two
days
40mg/kg: 10mg/kg twice for daily for two
days
No serious events were reported. Transient
dizziness and nausea weremore commonly
reported (higher dose first):
Dizziness: 40% versus 25%
Nausea: 25% versus 30%
A few events of vomiting, headache and
abdominal pain were also reported
Omer 1978 SDN 176 60 mg/kg: 15 mg/kg twice daily for 2 days
40 mg/kg: 20 mg/kg daily for 2 days
No serious adverse events was recorded.
Transient dizziness was more commonly
reported (higher dose first):
Dizziness: 15% versus 8%
Few minor abdominal pain, headache and
vomiting were also reported
Teesdale 1984 MWI 95 50 mg/kg single dose
40 mg/kg single dose
No serious adverse events was recorded.
Transient dizziness, nausea and vomiting
weremost commonly reported and did not
differ between dose
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Table 10. Commonly used dosing schedule of oxamniquine and praziquantel according to location
Trial Location (country) Dose
Oxamniquine (mg/kg) Praziquantel (mg/kg)
South America
Branchini 1982 BRA Brazil 13.8 45.4
da Cunha 1986 BRA Brazil 18 65
da Cunha 1987 BRA Brazil - 60, 120, 180
da Silva 1986 BRA Brazil 15 55
Fernandes 1986 BRA Brazil 15 70
Ferrari 2003 BRA Brazil 10 180
Katz 1979a BRA Brazil - 20, 40, 60
Katz 1979b BRA Brazil - 50
Katz 1981 BRA Brazil - 30, 30, 50
Katz 1982 BRA Brazil 20 65
Lambertucci 1982 BRA Brazil 20 -
Queiroz 2010 BRA Brazil - 50, 80
Rezende 1985 BRA Brazil 15 55
Zwingenberger 1987 BRA Brazil 15 40
North Africa
Abdel Rahim 1988 SDN Sudan 20, 40, 60 -
de Jonge 1990 SDN Sudan 60 40
Homeida 1989 SDN Sudan 40
Ibrahim 1980 SDN Sudan 40, 60 -
Kardaman 1983 SDN Sudan - 40
Omer 1978 SDN Sudan 30, 40, 60 -
Omer 1981 SDN Sudan - 30, 40
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Table 10. Commonly used dosing schedule of oxamniquine and praziquantel according to location (Continued)
Barakat 2005 EGY Egypt - 40
Botros 2005 EGY Egypt - 40
Metwally 1995 EGY Egypt - 40
East Africa
Ayele 1984 ETH Ethiopia 30, 40, 60 -
Ayele 1986 ETH Ethiopia 30, 40, 60 -
Jaoko 1996 KEN Kenya - 40
Olds 1999 KEN Kenya - 40
Taddese 1988 ETH Ethiopia 15, 30 40
Teesdale 1984 MWI Malawi 30, 40, 50 40
Rugemalila 1984 TZA Tanzania 15 40
Tweyongyere 2009 UGA Uganda - 40
West Africa
Shafei 1979 NGA Nigeria 15, 30 -
De Clercq 2000 SEN Senegal - 40
Guisse 1997 SEN Senegal - 40, 60
Stelma 1997 SEN Senegal 20 40
Central Africa
Gryseels 1989a BDI Burundi 20, 30, 40 -
Gryseels 1989b BDI Burundi - 20, 30, 40
Southern Africa
Gupta 1984 ZMB Zambia 30, 40, 60 -
Sukwa 1993 ZMB Zambia - 40
de Clarke 1976a ZWE Zimbabwe 15, 20 -
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Table 10. Commonly used dosing schedule of oxamniquine and praziquantel according to location (Continued)
de Clarke 1976b ZWE Zimbabwe 30, 40 -
de Clarke 1976c ZWE Zimbabwe 50, 60 -
Taylor 1988 ZWE Zimbabwe - 10, 20, 30, 40
Middle East
Al Aska 1990 SAU Saudi Arabia 25 40
Table 11. Adverse events: different oxamniquine dose versus praziquantel (40 mg/kg)
Trial No. of participants Comparison Remarks
Al Aska 1990 SAU 200 Oxamniquine (25 mg/kg) single dose
Praziquantel (40 mg/kg) single dose
One serious adverse event (seizure) was
recorded in the oxamniquine 25 mg/
kg group. Transient dizziness, abdominal
pain and nausea were most commonly re-
ported (oxamniquine first):
Dizziness: 36% versus 20%
Abdominal pain: 25% versus 12%
Nausea: 10% versus 8 %
Branchini 1982 BRA 101 Oxamniquine (14 mg/kg) single dose
Praziquantel (45 mg/kg) single dose
No serious adverse events were recorded.
Adverse events were minor and transient.
Dizziness, abdominal pain and nausea
were most frequently reported (oxam-
niquine first):
Dizziness: 44.2% versus 46.9%
Abdominal pain: 3.8% versus 24.5%
Nausea: 5.8% versus 8.2%
Rugemalila 1984 TZA 72 Oxamniquine (15 mg/kg) single dose
Praziquantel (40 mg/kg) single dose
No serious adverse events were recorded.
Transient abdominal pain and drowsiness
were commonly reported (oxamniquine
first):
Abdominal pain: 16% versus 63%
Drowsiness: 25% versus 11%
Taddese 1988 ETH 200 Oxamniquine (15 mg/kg) single dose
Oxamniquine 30 mg/kg :15 mg/kg twice
in one day
Praziquantel (40 mg/kg) single dose
One serious adverse event (seizure) was
recorded with oxamniquine 30 mg/kg.
Adverse events were minor and transient.
Dizziness and abdominal pain were com-
monly reported (oxamniquine lower dose
first):
Dizziness: 22%, 16% versus 20%
Abdominal pain: 20%, 28% versus 24%
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Table 11. Adverse events: different oxamniquine dose versus praziquantel (40 mg/kg) (Continued)
Teesdale 1984 MWI 119 Oxamniquine (30 mg/kg) single dose
Oxamniquine (40 mg/kg) single dose
Oxamniquine (50 mg/kg): 25 mg/kg
twice in one day
Praziquantel (40 mg/kg) single dose
No serious adverse events were recorded.
Transient dizziness was commonly re-
ported among participants receiving ox-
amniquine. There was no difference in
events between oxamniquine 30, 40 and
50 mg/kg (oxamniquine lower dose first)
:
Dizziness: 30.8%, 29.2%, 30.8% versus
8.3%
Table 12. Adverse events: oxamniquine plus praziquantel versus oxamniquine plus praziquantel
Trial No. of participants Comparison Remarks
Creasey 1986 ZWE 59 Oxamniquine (4 mg/kg) plus praziquantel
(8 mg/kg) versus oxamniquine (10 mg/kg)
plus praziquantel (20 mg/kg)
Oxamniquine (7.5 mg/kg) plus
praziquantel (15 mg/kg) versus
praziquantel (20 mg/kg) plus oxamniquine
(10 mg/kg)
No serious adverse events. Adverse events
were minor and did not differ between
combinations. One child reported dizzi-
ness five minutes after treatment but re-
quired no further treatment and was well
the following day. About 70% of children
reported abdominal discomfort but these
were transient and had resolved the follow-
ing day
Table 13. Non-randomized exploratory analysis of age (praziquantel)
Dose (mg/kg) Time point (months) Study Number failed/number examined (%)1
Children (<20 years) Adults (≥20 years)
20 1 Gryseels 1989b BDI 48/109 (44) 26/61 (43)
3 Gryseels 1989b BDI 49/100 (49) 16/54 (30)
6 Gryseels 1989b BDI 61/109 (56) 19/58 (33)
12 Gryseels 1989b BDI 60/101 (59) 21/59 (36)
30 1 Gryseels 1989b BDI 37/93 (40) 2/48 (4)
Gryseels 1989c BDI 37/104 (36) 12/65 (18)
3 Gryseels 1989b BDI 38/91 (42) 4/40 (10)
Gryseels 1989c BDI 37/98 (38) 10/66 (15)
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Table 13. Non-randomized exploratory analysis of age (praziquantel) (Continued)
6 Gryseels 1989b BDI 41/94 (44) 6/46 (13)
Gryseels 1989c BDI 40/94 (43) 19/61 (31)
12 Gryseels 1989b BDI 55/91 (60) 9/44 (20)
Gryseels 1989c BDI 73/92 (79) 19/51 (37)
40 1 Gryseels 1989b BDI 22/94 (23) 5/42 (12)
Gryseels 1989c BDI 18/81 (22) 2/54 (4)
3 Gryseels 1989b BDI 23/87 (26) 1/32 (3)
Gryseels 1989c BDI 26/83 (31) 11/54 (20)
6 Gryseels 1989b BDI 29/92 (32) 4/37 (11)
Gryseels 1989c BDI 23/76 (30) 10/51 (20)
12 Gryseels 1989b BDI 34/84 (40) 10/38 (26)
1Number failed/number examined (%) presented for the praziquantel treatment group of each study that presents data for adults and
children separately.
Table 14. Non-randomized exploratory analysis of age (oxamniquine)
Dose (mg/kg) Time point (month) Study Number failed/number examined (%)1
Children (< 20 years) Adults (≥ 20 years)
20 1 Abdel Rahim 1988 SDN 11/41 (26) 3/55 (6)
Gryseels 1989a BDI 31/57 (60) 17/95 (17)
3 Abdel Rahim 1988 SDN 6/41 (15) 4/55 (7)
Gryseels 1989a BDI 30/56 (54) 22/102 (22)
6 Abdel Rahim 1988 SDN 10/41 (24) 9/55 (16)
Gryseels 1989a BDI 29/49 (59) 20/86 (23)
12 Gryseels 1989a BDI 38/41 (93) 20/83 (24)
30 1 Gryseels 1989a BDI 16/42 (38) 2/76 (3)
3 Gryseels 1989a BDI 12/46 (26) 8/77 (10)
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Table 14. Non-randomized exploratory analysis of age (oxamniquine) (Continued)
6 Gryseels 1989a BDI 22/41 (54) 3/62 (5)
12 Gryseels 1989a BDI 24/39 (62) 10/67 (15)
40 1 Abdel Rahim 1988 SDN 2/43 (5) 1/57 (2)
Gryseels 1989a BDI 8/49 (19) 2/67 (3)
3 Abdel Rahim 1988 SDN 5/43 (12) 3/57 (5)
Gryseels 1989a BDI 10/51 (20) 5/65 (8)
6 Abdel Rahim 1988 SDN 13/31 (42) 5/57 (9)
Gryseels 1989a BDI 24/42 (57) 11/62 (18)
12 Gryseels 1989a BDI 25/38 (66) 11/60 (18)
60 1 Abdel Rahim 1988 SDN 2/42 (5) 0/58 (0)
3 Abdel Rahim 1988 SDN 10/42 (24) 1/58 (2)
6 Abdel Rahim 1988 SDN 16/42 (38) 1/58 (2)
1Number failed/number examined (%) presented for the oxamniquine treatment group of each study that presents data for adults and
children separately.
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Last assessed as up-to-date: 16 October 2012.
Date Event Description
6 November 2012 New citation required and conclusions have changed This review update has been prepared by new authors
(Danso-Appiah A, Olliaro PL, Donegan S, Sinclair D
and Utzinger J). Each section of the review has been
rewritten and updated, including the results and con-
clusions
6 November 2012 New search has been performed This is a new review with a fresh authorship team, re-
placing a previous version. The previous version in-
cluded 13 trials and the last search was in 2005 and only
reported parasitological failure. The current version in-
cludes 52 trials, includes percentage egg reduction as an
outcome, and includes new trials evaluating artesunate.
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(Continued)
All data have been re-extracted. Each section of the re-
view has been rewritten. Results are summarized using
a Summary of Findings table. Data in the intervention
arm in relation to cure are explored by age
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